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      Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United 
States and the fifth leading cause of cancer-related mortality worldwide.   Pancreatic cancer 
is a big challenge in large due to the lack of early symptoms. In addition, drug resistance is a 
major obstacle to the success of chemotherapy in pancreatic cancer. The underlying 
mechanism of drug resistance in human pancreatic cancers is not well understood. Better 
understanding of the mechanism of molecular pathways in human pancreatic cancers can 
help to identify the novel therapeutic target candidates, and develop the new preventive and 
clinic strategies to improve patient survival.  We discovered that TAK1 is overexpressed 
in pancreatic cancer cell lines and patient tumor tissues. We demonstrated that the elevated 
activity of TAK1 is caused by its binding partner TAB1.  Knocking down of TAK1 
in pancreatic cancer cells with RNAi technique resulted in cell apoptosis and significantly 
reduces the size of tumors in mice and made a chemotherapy drug more potent.  Targeting 
the kinase activity of TAK1 with the selective inhibitor LY2610956 strongly synergized in 
vitro with the antitumor activity of gemcitabine, oxaliplatin, or irinotecan 
v 
 
on pancreatic cancer cells.  These findings highlighted that TAK1 could be a potential 
therapeutic target for pancreatic cancer.  
      We also demonstrated that TAK activity is regulated by its binding protein TAB1. We 
defined a minimum TAB1 sequence which is required and sufficient for TAK1 kinase 
activity.  We created a recombinant TAK1-TAB1 C68 fusion form which has highly kinase 
activity. This active form could is used for screening TAK1 inhibitors.  
 
      In addition, several posttranslational modifications were identified in our study. The 
acetylation of lysine 158 on TAK1 is required for kinase activity. This site is conserved 
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1.1.1. Overview of pancreas 
 
      1.1.1.1 Function and anatomy of Pancreas:  In humans, the pancreas is located 
posterior to the stomach and associated with the duodenum. The pancreas is composed of 
five regions: a head, neck, body, tail and uncinate process (Fig.1). The uncinate process of 
the pancreas hooks the superior mesenteric artery and vein. The head is the rightmost portion 
connected to the duodenum. The neck connects the head and the body portion. The body is 
the main part of the pancreas that extends towards the tail. The tail of the pancreas is the 
leftmost portion next to the spleen. 
 
Figure 1. Anatomy of human pancreas.   
http://pathology.jhu.edu/pancreas/BasicOverview2.php?area=ba. Reprinted 
by permission from Dr. Ralph Hruban 
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      The pancreas includes exocrine glands and endocrine glands. The exocrine part consists 
of acinar cells that make and release digestive enzymes into the small intestine, which are 
required for the digestion of carbohydrates fats and proteins. The endocrine part consists of 
the islets of Langerhans which are surrounded by exocrine pancreatic acinar cells. The islets 
of Langerhans are composed of four different types of cells: α cells secret glucagon, β cells 
secret insulin, δ cells secret somatostatin and PP cells produce the pancreatic polypeptide[1]. 
 
      1.1.1.2. The origin of pancreatic cell lineage: Many of the genes that control 
differentiation and proliferation in the normal developmental process are mutated in the 
progression of cancer.  There is a well known idea that cancer is an aberrant recapitulation of 
embryogenesis because they share many of the same genes with each other.  Therefore, the 
knowledge of the molecular signaling pathway involved in cell-fate determination of the 
progenitor cells during embryogenesis and organogenesis is also important for understanding 
cancer progression.  We will briefly review how pancreatic cells originate and differentiate as 
below.   
 
      The pancreas arises from the fusion of the dorsal and ventral buds in the endoderm of the 
foregut at E9.5 in mice [2-4].  Several signaling molecules have been identified to determine 
the differentiation of pancreas (Fig.2).  Sonic hedgehog (Shh) was expressed in stomach and 
duodenal endoderm at the stage E12.5 of mouse, but absent in pancreatic endoderm [5]. 
Ectopic expression of shh in the pancreatic epithelium lead to smooth muscle and interstitial 
cells [6-8].  The notochord secretes some signaling molecules including fibroblast growth 
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factor 2 (FGF2) and activin- βB that belong to the TGF-β during the early stage of pancreas 
development. Both of them block the expression of Shh and the Shh receptor, Ptc1 and 
therefore induce the expression of a variety of transcriptional factors including Pdx1, 
Isl1, and Pax6 all of which play the important roles in the development of pancreas [9]. 
 
      Notch signaling controls pancreatic cells determination at the different stage of pancreas 
development.  Activated Notch receptors bind to the DNA-binding protein RBP-Jk therefore 
to lead to the expression of the negative basic helix–loop–helix (bHLH) HES genes which 
block the expression of ngn genes [10-16]. Loss of Notch promotes ngn3 expression to 
induce the pancreatic endocrine cell fate [10]. The exocrine markers such as amylase were 
not detectable in the transgenic mice misexpressing activated Notch driven by PDX promoter. 
Two independent labs demonstrated that Notch inhibited not only the endocrine but also 
exocrine cell fate determination and thereby kept the progenitor cells at the undifferentiated 
state [17, 18].   
 
      An elegant study using cre-loxp genetic system identified several specific transcription 
factors [19]. In this study, they demonstrated that all three groups including islets, exocrine 
and ductal cells originate from the same progenitors expressing the transcription factor pdx1. 
All four types of islet cells including α, β, δ and PP cells are derived from the parent cells 
that express ngn3 transcription factors. However, ngn3 was not detected in the majority of 
acini or mature pancreatic duct cells. These studies strongly support that ngn3 transcriptional 













Figure 2. Cell differentiation signalling pathways in pancreatic development. The genes 
that play an important role at the different stages of normal pancreatic development steps 






1.1.2. Overview of pancreatic cancer 
 
      The most of pancreatic cancers arise from the ductal exocrine glands and are called 
adenocarcinoma of the pancreas [20, 21].Pancreatic cancer is the fourth leading cause of 
cancer-related mortality in the United States and the fifth leading cause of cancer-related 
mortality worldwide. Most people with pancreatic cancer in U.S.A. have developed 
metastatic cancer by the time that pancreatic cancer is diagnosed. According to the estimation 
of the American Cancer Society, approximately 43140 cases will be diagnosed with this 
cancer and 36800 patients will die of it in 2010. These numbers indicate the difficulties in the 
relative lack of curative approaches. The mechanism of invasion and metastasis in human 
pancreatic cancers is not well understood. Better understanding the origin and biology of 
invasive pancreatic cancer would therefore become an extreme important issue. 
 
      1.1.2.1. Causes and risk factors of pancreatic cancer: Epidemiology studies have 
defined several risk factors related with pancreatic cancer. These factors include personal 
habits and genetic background. A lot of reports have demonstrated heavy alcohol 
consumption and smoking are positively associated with pancreatic cancer [22-24]. 
 
      1.1.2.2. The classification of ductal adenocarcinoma of the pancreas: Pancreatic 
ductal adenocarcinoma (PDAC) is the most cause and the most malignant type of pancreatic 
tumor cases.  Important progress in the histopathologic and clinical studies has been made 
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that ductal adenocarcinoma primarily arise from premalignant precursor lesions. Three 
premalignant precursor lesions have been identified to progress to invasive cancer. These 
lesions have been classified into pancreatic intraepithelial neoplasia (PanIN), mucinous 
cystic neoplasms (MCNs), and intraductal papillary mucinous neoplasms (IPMNs) [25, 26]. 
We will review the classification of these lesions, including their distinguishing features and 
the molecular alterations associated with them below. 
      1.1.2.2.1. Pancreatic intraepithelial neoplasia (PanIN):  PanIN is the most common 
non-invasive precursor lesion of pancreatic cancer. PanINs are defined as neoplastic 
epithelial proliferations (increased incidence of abnormal ductal structures) in the smaller 
caliber pancreatic ducts of patients with pancreatic adenocarcinoma.  PanINs are graded into 
four groups according to the morphological criteria, cytological and architectural atypia: 
PanIN-1A, PanIN-1B, PanIN-2 and PanIN-3 [27]. There is a lot of morphological difference 





Figure 3. Genetic progression model of pancreatic adenocarcinoma. 
Nature Reviews Cancer 2, 897-909 (December 2002). Reprinted by permission from 







      1.1.2.2.1.1. PanIN-1A:  (Pancreatic Intraepithelial Neoplasia 1-A): Neoplastic PanIN-1A 
represents the earliest step towards neoplasia. Grade of atypism is the lowest in PanIN-1A. 
As described in detail elsewhere [27], PanIN-1A stage is characterized by the appearance of 
a columnar, mucinous epithelium. These flat epithelia contain abundant supranuclear mucin 
and basally located, round to ovoid nuclei with minimal atypia. The membrane of basement 
is perpendicular to the nuclei if oval. There is much histological overlap between non-
neoplastic flat hyperplastic lesions and flat neoplastic lesions without atypia. The neoplastic 
nature of PanIN-1A has not been well defined because they are also consistently found in 
histologically normal human pancreas in many cases [27]. 
 
      1.1.2.2.1.2. PanIN-1B: (Pancreatic Intraepithelial Neoplasia 1-B): The epithelial cells in 
PanIN-1B are similar to those in PanIN-1A, but in contrast to flat epithelial cells in PanIN-
1A, PanIN-1B lesions have increased crowding of tall columnar cells with papillary or 
micropapillary projections. These epithelial cells have pseudostratified architecture and are 
basally located [27].  
 
      1.1.2.2.1.3. PanIN-2: (Pancreatic Intraepithelial Neoplasia 2): The details of PanIN-2 
have been described [27]. PanIN-2 lesions exhibit a flat or papillary organization. However, 
some mild cytological abnormalities are observed the mucinous epithelial lesions such as 
hyperchromatism and pseudo-stratification. In addition, nuclear crowding results in the 
enlarged nuclei. Cell polarity is lost.  These nuclear abnormalities are less striking than those 
seen in PanIN-3. Rare mitoses characterized by non-atypical and non-luminal (not apical) are 
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observed in. PanIN-2 lesions show In contrast to PanIN-3, PanIN-2 lesions generally do not 
show dramatically cytologic abnormalities and true cribriforming luminal necrosis [27, 28]. 
 
      1.1.2.2.1.4. PanIN-3: (Pancreatic Intraepithelial Neoplasia 3): The epithelial lesions are 
usually papillary or micropapillary in the architect, but in contrast to PanIN-2 lesions, they 
are rarely flat. PanIN-3 lesions are characterized by occurrence of severe cytologic 
abnormalities. Budding off into the lumen and true cribriforming are observed in the 
epithelial cells. Luminal necroses are observed in some cases. Nuclear polarity is 
significantly lost in PanIN-3 lesions. Mucinous cytoplasm display an orientation towards the 
basement membrane and dystrophic goblet cells display an orientation of nuclei towards the 
lumen. In addition, prominent (macro) nucleoli and abnormal or apical mitoses are detected. 
PanIN-3 epithelial lesions are similar to carcinoma cells without invasion of the basal 
membrane, so they are referred to as “carcinoma in situ”. PanIN-3 is a late step in the course 
of tumorigenesis [27, 28]. 
 
      1.1.2.2.1.5. Genetic alterations in pancreatic adenocarcinoma: A dramatic shortening 
of telomere length in PanIN-1A has been observed in PanIN-1A lesions. Telomere 
shortening occurs in with a higher frequency than other genetic abnormalities.  Telomere 
shortening has been one of the earliest demonstrable genetic aberrations in pancreatic 




      The molecular genetics PDAC has indicated that cancer genes are involved in PDAC 
progression. Genetic events and cancer signaling pathways have been linked the histological 
features of defined grade of PDAC progression. How these molecular events   contribute to 
the characteristics of the neoplasms remains to be determined. 
 
      1.1.2.2.1.5.1. K-RAS oncogene is one of the earliest genetic abnormalities identified in 
the development of PDAC. The frequency of K-ras mutations reported in PDACs differed 
from study to study, but every study unambiguously showed that the frequency of KRAS 
mutations increases with the progression of PanIN from low-grade to high-grade with the 
mutation rate up to 100% for PanIN-3 lesions[30-32]. K-RAS is a GTPase which belongs to 
GTP-binding protein family. The Ras GTPase-activating protein (GAP) is required for 
GTPase hydrolyze to substrate. K-ras point mutation at codon 12 (substitution of GAT for 
GGT) results in insensitivity to GAP and therefore attenuate the intrinsic rate of GTP 
hydrolysis [33, 34]. Therefore, this leads to the formation of constitutively active (GTP-
bound) protein which is independent of growth factor stimulation. Activated K-RAS has 
been reported to function in several signaling pathways such as RAF-mitogen-activated 
kinase (MAPK) pathway, phosphoinositide-3-kinase/AKT signaling, and Ral GDS pathway 
[35]. G12D K-ras mutation is related to resistance to TRAIL treatment in human pancreatic 
and lung cancer cell lines [36]. These downstream signaling elements are thought to 
contribute to PDAC progression.  
 
      MAP kinases are serine/threonine-specific protein kinases that control multiple cellular 
processes, such as gene expression, mitosis, differentiation, and cell survival/apoptosis[37]. 
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The dominant negative forms of MEKK1, ERK1 and ERK2 inhibited the survival of colonies 
in pancreatic cancer cell lines [38]. Pharmacologic inhibitors of MEK induced cell cycle 
arrest in pancreatic cancer cell lines[39].A lot of studies by conditional knockout, xenograft 
and pharmacological inhibition have shown PI3K pathway plays a key role in PDAC 
progression [40-42]. RAL GTPases belong to the RAS subfamily. It has been found that 
RAL A was activated in many PDAC cell lines. Tumorigenicity of RAS-transformed human 
is inhibited by knockdown of RAL A using siRNA [43]. 
 
      1.1.2.2.1.5.2. P21WAF1/CIP1 overexpression was found in 16% of patients with PanIN-1A 
lesions and increased in frequency in PanIN-2 and PanlN-3 [44].  The activity of cyclin-
CDK2 and cyclin-CDK4 complexes is blocked by the binding of P21WAF1/CIP1  and thereby 
and cell cycle progression is regulated. 
 
      1.1.2.2.1.5.3. HER-2/neu (epidermal growth factor receptor homologue) is 
overexpressed in 82% (P = .008 vs. normal) of ducts with flat mucinous hyperplasia [45]. 
HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor that is highly 
extensive homologous to the epidermal growth factor receptor. HER2/neu) play a key role in 
the tumorigenesis. 
 
      1.1.2.2.1.5.4. Loss of p16 protein expression was observed in all PanIN lesions as early 
as PanIN-1A [31, 46].  P16INK4A and p14ARF are two tumor suppressors which are encoded by 
the CDKN2A/INK4A gene on chromosome 9p21. P16INK4A and p14ARF have distinct first 
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exons and alternative reading frames with shared downstream exons [47]. P16INK4A is a cell 
cycle checkpoint protein which blocks phosphorylation of RB, therefore inhibiting cell cycle 
entry into DNA synthesis phase. ARF can stabilize tumor suppressor p53 by preventing 
nucleo-cytoplasmic shuttling of Mdm2 [48]. INK4A is inactivated due to mutation, loss or 
promoter hypermethylation in up to 95% of human pancreatic cancers [31].   
 
      1.1.2.2.1.5.5. The p53 tumor suppressor mutations in the DNA-binding domain were 
identified in later-stage PanINs that are characterized by dysplasia [31, 49, 50]. The later loss 
of p53 and its functions decrease DNA repair checkpoint responses and leads to genomic 
instability that contribute to PDAC progression. 
 
      1.1.2.2.1.5.6. Loss of SMAD4 is identified in less than 50% of PanIn-3 lesions and 
considered as a late genetic event in PDAC [31].  Inactivation of smad4 Smad 4 is key 
modulators of TGF- β super family.  SMAD4 can bind to receptor regulated SMADs (R-
SMADs), such as SMAD1 or SMAD2 to form the complexes. The complexes translocate 
into the nucleus and act as transcriptional factors. SMAD4 play a key role in differentiation, 
apoptosis, and the cell cycle. 
 
      1.1.2.2.1.5.7. BRCA2 mutation is found in familial pancreatic cancers [51].  BRCA2 
plays a role in DNA repair and thereby maintains genomic stability. Loss of the wild-type 
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BRCA2 allele has been observed in those carriers of the BRCA2 germline heterozygous 
mutations of BRCA2 in the late stage of PDAC. 
 
      1.1.2.2.1.6. Other signaling pathways in PDAC: 
 
      1.1.2.2.1.6.1. Growth factor pathways in pancreatic cancer:  Grow factors are the 
proteins that bind to their specific membrane receptors on the outside of the cell. Grow 
factors promote cellular proliferation and differentiation. Multiple growth factor pathways 
are dysregulated in pancreatic cancer cells. Transforming growth factors beta (TGF-β) is 
overexpressed in pancreatic cancer cells.  As discussed before, the smad4, which is the 
member of TGF-β pathway cascade, is lost in pancreatic cancer cells. Epidermal growth 
factor (EGF), Vascular Endothelial Growth Factor (VEGF), insulin-like growth factor (IGF) 
fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and their receptors are 
expressed at higher levels in pancreatic cancer cells than in normal pancreas[21]. 
 
      1.1.2.2.1.6.2. The serine/threonine kinase LKB1 regulates cell polarity and energy 
sensing by phosphorylating AMPK [52]. Mutations or deletions in LKB1 lead to Peutz-
Jeghers syndrome [53]. LKB1 is also lost in 4%–6% of human pancreatic cancers [54], but 




      1.1.2.2.1.6.3. NF-κB transcriptional factor in pancreatic cancer: NF-κB is a family of 
pleiotropic transcription factors that regulate the expression of a large number of genes 
involved in inflammatory responses, apoptosis, oncogenesis, and metastasis. Mammalian 
NF-B family consists of five members: NF-κB1 (p50 and its precursor, p105), NF-κB 2 
(p52 and its precursor, p100), c-Rel, RelA (p65), and RelB.  All of Rel/NF-κB proteins 
contain a highly conserved Rel homology domain (RHD), which mediates DNA-binding, 
inhibitor IB interaction, dimerization and nuclear localization[55][55][55][55][55]. NF-κB 
family members can form heterodimers and homodimers with most other family members, to 
generate gene regulatory complexes with different properties. The classical pathway of NF-
κB is activated by a heterodimer of p50 and p65, which is usually the most abundant of the 
transactivating complexes [56].  
 
      The activity of NF-B is regulated by a shuttling mechanism between cytoplasm and 
nucleus. The interaction of NF-B with the inhibitors, known as IB, keeps inactive NF-
B/IB complexes in the cytoplasm.  In response to cytokine stimulation, the inhibitor IB is 
phosphorylated by IB kinase complex (IKK), and thereby NF-B translocates into nucleus 
to induces expression of downstream target genes such as VEGF, IL-6, IL-8 and Bcl-xL [56, 
57]. It has become increasingly evident that members of the NF-B and IB families plays a 
key role in the development of cancer. Previous studies in our lab have showed NF-B is 
constitutively activated in nearly 70% human pancreatic cancer tissues and most pancreatic 
cancer cell lines[58, 59]. The dominant-negative mutant IB (S32, 36A) blocked 
tumorigenesis and liver metastasis of pancreatic cancer cells [58, 59].  
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      1.1.2.2.2. Mucinous cystic neoplasms (MCNs) of the pancreas are uncommon tumors 
compared with pancreatic intraepithelial neoplasia (PanIN). Basically, they are mucin-
producing (filled with mucinous fluid) cystic tumors, characterized by ovarian-type stroma 
[60]. Most pancreatic MCNs are more frequently located in the body and the tail than in the 
head of the pancreas. Most of MCNs are found in middle-aged females [61]. MCNs appeared 
usually unilocular and occasionally multilocular. These cysts are lined by columnar mucin-
containing epithelial cells which are supported by ovarian-like cellular stroma composed of 
densely packed spindle cells. Generally, MCNs do not communicate with the pancreatic duct 
system[60]. 
 
     Immunohistology has demonstrate that stroma of ovarian MCN was strongly 
immunopositive for α-smooth muscle actin (α-SMA) and vimentin and focally positive for 
desmin, and strong nuclear staining with estrogen and progesterone receptor [62].  
 
      The dysplasia of MCNs can be graded according to degree of cellular atypia. Low -grade 
dysplasia is characterized by uniform nuclei with minimal atypia, developing to middle grade 
dysplasia with moderate cytologic and architectural atypia, to high-grade dysplasia with 
significant architectural and cytologic atypia [60].  
 
      Our knowledge about genetic and epigenetic alterations in MCNs is still much less than 
that of ductal adenocarcinoma due to the very limit number neoplastic cells, however, MCNs 
have been shown some genetic alterations in common with those of PanINs as discussed 
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before. KRAS mutations have been found in 20% of mild dysplasia, 33% moderate dysplasia, 
and 89% of carcinoma in situ and invasive carcinoma [63]. Immunohistochemical studies 
have demonstrated overexpression of the tumor suppressor p53 in MCNs with the high-grade 
dysplasia but not in MCNs with low-grade dysplasia [63, 64]. Loss of Smad4/Dpc4 
expression has been found in advanced invasive MCNs [65]. In addition, Global analysis of 
gene expression has found a lot of over-expressed genes in MCNs including S100 calcium-
binding protein P (S100P), Annexin 14 (ANX14), Prostate stem cell antigen (PSCA) [66]. 
 
     1.1.2.2.3. Intraductal papillary mucinous neoplasms (IPMNs) are an uncommon type 
of pancreatic neoplasm characterized by non-invasive mucin producing, intraductal papillary 
or rarely flat epithelia. These epithelia arise from the main pancreatic duct or branch ducts, 
with ductal dilation and mucin retention in the pancreatic ducts [67].  
 
      As MCNs, IPMNs can also be graded according to degree of cytologic and architectural 
atypia, ranging from low-grade dysplasia (intraductal papillary mucinous adenoma), to IPMN 
with moderate dysplasia, to IPMN with high-grade dysplasia (intraductal papillary mucinous 
carcinoma). Most IPMN grow slower and are less aggressive than ductal adenocarcinoma. 
One third of incidences of IPMNs are associated with invasive adenocarcinoma [68].  
 
    According architectural patterns, histology and mucin expression profile of the epithelium, 
IPMNs can be group into four subtypes:  the gastric type, intestinal type, pancreatobiliary 
type, and oncocytic type. The gastric-type express MUC5AC but are negative for MUC1 and 
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MUC2. The intestinal-type IPMN express MUC2 and MUC5AC but are negative for MUC1. 
The pancreatobiliary-type IPMN is at least focally positive for MUC1 and consistently 
expresses MUC5AC but not MUC2. The oncocytic-type IPMN expresses MUC5AC 
consistently and MUC1 and MUC2 focally [68]. 
 
      A lot of studies have demonstrated genetic alterations in IPMNs. The frequency of KRAS 
mutations increases with the progression of the grades of dysplasia in IPMNs [69]. In 
activation of tumor suppressor p53 is detected in high-grade dysplasia of IPMNs [70]. In 
contrast to PanINs, IPMNs showed the normal expression of SMAD4/DPC4 [68].  In 
addition, gene expression profiles in IPMNs have been identified by cDNA microarray 
technology. 62 up-regulated and 58 down-regulated genes have been found. Three members 
of the trefoil factor family (TFF1, TFF2, and TFF3) are identified as the most highly up-
regulated genes in IPMNs. The mutations in the phosphoinositide-3-kinase catalytic-α 
(PIK3CA) gene have been found at the rate of 11% [71]. 
 
      1.1.2.3. Mouse models in pancreatic cancer studies: Molecular genetics and 
epidemiology of pancreatic cancer provide us the best evidence that pancreatic cancer arises 
from premalignant precursor lesions. Furthermore, the studies using mouse model of 
pancreatic cancer have demonstrate genetic mutations are responsible for progression of 




    Activated KrasG12D mutation has been targeted the pancreatic epithelium by Cre 
recombinase expression. The Pdx1 and Ptf1-p48 promoters are specific active in the 
pancreatic cell types and use to delete LoxP-flanked Stopper Element to activate KrasG12D 
expression. KrasG12D mutation mice show a gradual, age-dependent progression of lesions 
which mimic human PanINs-I–III after a long latency [72]. KrasG12D mutation combined 
with a conditional null allele of p53 [73] or a p53 R273H knock-in [74] allele resulted in 
rapid progression of PDAC. Similarly, KrasG12D mutation combined with a conditional null 
allele of p16 developed PDAC with shorter latency than KrasG12D alone [73]. These 




      Transforming growth factor-beta (TGF-beta) activation kinase (TAK1, MAP3K7) is a 
member of MAPKKK family. It was firstly identified in mouse by a yeast genetic screen 
using histidine as the selection marker. In the original study, TAK1 was showed to activate 
Plasminogen Activator Inhibitor-1 (PAI-1) promoter after TGF-β or BMP-4 stimulation.  
These experiments demonstrated that TAK1 may be a mediator of TGF-β signaling pathway 
[75]. 
 
      1.1.3.1. TAK1 in C.elegans. TAK1 homolog in C.elegans, MOM-4 was initially 
identified as an anterior-posterior (AP) polarity gene whose mutation resulted in the defects 
in polarity decisions in the early embryonic development.  In the nematode Caenorhabditis 
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elegans, 4-cell stage embryonic cell, or blastomere, called EMS divides asymmetrically 
along the anterior-posterior axis [76].  The E produces blastomere endodermal cells, while 
the MS blastomere gives rise primarily to mesodermal cells [77, 78].  
 
      POP-1 is a member of a transcriptional factor family which contains the high mobility 
group (HMG or HMGB) domain controlled by Wnt signaling.  POP-1 is a maternal gene 
which is asymmetrically expressed at lower levels in the posterior daughter, 
E blastomere than the anterior daughter, MS blastomere in EMS. Genetic analysis 
demonstrated that mom-4 may act as the upstream of pop-1 and synergize with other mom 
mutant belonging to Wnt/WG components [76, 79]. MOM-4 is required for the WRM-1/LIT-
1-dependent phosphorylation of POP-1 which in turn down-regulate POP-1 activity [76, 
80].  Mom-4 is homologous to vertebrate TAK1.  Lit-1 is homologous to nemo-like kinase 
(NLK) which is also shares 45% identical amino acids with human p38 MAP kinase and 43% 
identical amino acids with human ERK1 within the kinase domain [76]. These data support 
that a MAP kinase may contribute to AP cell determination during the early development of 
in C.elegans. 
 
      A binding protein called TAB1 is required for TAK1 kinase activity. TAP-1 encodes the 
homolog of vertebrate TAB1. Co-expression of MOM-4 and TAP-1 stimulate MOM-4 
MAP3K activity, which support that the function of TAK1 is highly conserved between 




      1.1.3.2. TAK1 in Drosophila. Drosophila TAK1 was identified a Drosophila genomic 
library using mouse TAK1 as the probe [81].  A variety of developmental defects in different 
tissue were caused by expressing mTAK1 transgenic flies.  A rough eye phenotype was 
observed in UAS-mTAK1/elav-GAL4 flies, whereas the antenna and distal parts of legs were 
missing in mTAK1/Dll-GAL4 flies. The activated form of mTAK1 in which the N-terminus 
is truncated caused early embryonic lethality. The size of the compound decreases by 30% in 
eye specific transgenic line compared with wild type flies. The active form of mouse TAK1 
had more severe effects on eye development in the transgenic lines. Eye size was reduced to 
less than 30% and ommatidial units were almost totally lost in the transgenic lines expressing 
mTAK1ΔN. These results demonstrated that mTAK1ΔN has more severe effect than full 
length mTAK1 in transgenic flies [81]. Coexpression of mTAK1 with hTAB1 resulted in 
much smaller eye than mTAK1 alone.  
 
      TAK1 play a very important role in the control of JNK activity in Drosophila. TAK1 can 
activate the expression of JNK downstream targets including pp and puc. TAK1 induced the 
phosphorylation of the Bsk protein and activate Hep-Bsk cascade.  Loss-of-function of 
bsk and hep suppressed the phenotype caused by the ectopic expression of TAK1. Both gain 
of function and loss of function experiments support that TAK1-JNK pathway induced 
apoptosis phenotype in Drosophila [81]. However, Genetic interaction analysis demonstrated 
that TAK1 may not be involved in p38 or TGF-β/Dpp signaling. The function of TAK1 may 




      TAK1 also play an essential role in NF-κB pathway of Drosophila. Genetic approach 
identified that TAK1 acts as upstream of the IKK complex and downstream of Imd. TAK1 is 
required for Imd activation stimulated by natural Gram-negative bacterial infection and 
controls antibacterial peptide gene expression in Drosophila. The expression of the    
Drosomycin-GFP reporter gene induced by Gram-negative bacteria strain E. carotovora 15 is 
significantly reduced in dTAK11 and DreddB118 mutants [82].  
 
      In Drosophila, downstream signaling of TAK1 diverges into two separate pathways. 
Both the IKK/Relish branches and JNK are mediated by TAK1 and play a role in innate 
immunity. The IKK/Relish regulated genes reflect a sustained response while the JNK 
regulated genes exhibit a transient effect.  Relish induces the proteasome-mediated 
degradation of TAK, therefore to negatively regulate JNK signaling [83]. 
 
      1.1.3.3. TAK1 in zebrafish. The limited study of TAK1 in zebrafish was focus on its 
function in development. TAK1 homolog in zebrafish shares 71% identical amino acids with 
mice. Alk1 is TGFβ type I receptor. The mutations of the zebrafish Alk1 ortholog violet 
Beauregard (vbg) resulted in cranial dilation which lead to the defect in blood circulation. 
The experiments using the injection of antisense morpholinos against TAK1 and Alk1 
demonstrated that they acted in the same pathway as they displayed a synergized effect on 
vascular development. The genetic interaction analysis put TAK1 in the downstream of 
ALK1 for vascular development as the overexpression of TAK1 rescued the defects caused 
by ALK1 mutation [84]. 
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      1.1.3.4. TAK1 in Xenopus. Not much is known about the function of TAK1 in Xenopus. 
Limited studies have shown that TAK1 play an important role in early embryonic 
development of Xenopus. Injection of TAK1 mRNA into four-cell stage embryos leads to 
apoptosis and embryos. Co-injection of human bcl-2 mRNA reversed apoptosis caused by 
TAK1 and induced the formation of normal embryos. These results support that 
overexpression of TAK1 results in apoptosis in Xenopus. The injection of TAK1∆N mRNA 
encoding the N-terminal truncated TAK1 resulted in apoptosis at lower doses than the full 
length TAK1. Although co-injection of xTAK1∆N mRNA and human bcl-2 mRNA into the 
ventral side did not exhibit phenotypes, co-injection of both the dorsal marginal zone of four-
cell embryos strongly induced ventralization of the  embryos.  These results demonstrated 
that TAK1∆N specifically induces the formation of ventral mesoderm, which is same as the 
phenotype induced by BMP-4. These results support that TAK1 and BMP-4 may act in the 
same signaling pathway [85]. 
 
      TAK1 acts as the downstream of BMP signaling at the early developmental stage of 
Xenopus. Injection of TAK1 kinase dead form (TAK1DN) mRNA blocked the ventralization 
of Xenopus embryos induced by the injection of the mRNA encoding the constitutively 
active form of the BMP-2/4 type I receptor. However, TAK1 kinase dead form did not 
repress the expression of a pan-mesoderm marker (Xbra) stimulated by fibroblast growth 
factor (FGF). Injection of TAK1KN mRNA also did not block the expression of dorsalization 
marker molecules induced by activin, the constitutively active activin type IB receptor or 
Smad2. These results indicate that TAK1 appears to be the specific downstream of BMP, 
smad pathway, but not activin [85]. 
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      Nemo-like kinase (NLK) is a downstream effector of TAK1. The injection of NLK 
specific translational inhibitor, morpholino-antisense oligonucleotide (MO) inhibited 
mesoderm induction at four-cell-stage. The whole-mount immunostaining by using a specific 
phosphorylation antibody demonstrate that STAT3 is phosphorylated at Ser 728 during the 
gastrula stage. Moreover, the injection of TAK1 MO greatly lowered STAT3 serine 
phosphorylation and the expression of Xbra, α-actin and Xnot induced by BMP, which are 
the mesodermal markers. These results demonstrate that TAK1, NLK and STAT3 cascade 
play a role in the early stage of Xenopus development [86]. 
 
      1.1.3.5. TAK1 in mouse. The functional role of mouse TAK1 in multiple signaling 
pathways has been intensively studied.  The following review will be focused on the role of 
TAK1 in the innate immunity pathways and development.  
       
      1.1.3.5.1. The role of TAK1 in cardiac development.  P19CL6 cell line originated from 
P19 mouse embryonic teratocarcinoma cells. P19CL6 cell line has been used as an in vitro 
cardiomyocyte differentiation system.  The treatment with 1% dimethyl sulfoxide induced 
most of P19CL6 cells to produce beating cardiomyocytes.  However, the expression of 
contractile protein genes and cardiac transcription factors is lost in the progeny cells, 
P19CL6noggin which constitutively expresses the BMP antagonist noggin. Therefore, 
P19CL6noggin cell no longer differentiate into beating cardiomyocytes. The differentiation 
of P19CL6 cells into beating cardiomyocytes was reduced by TAK1 dominant negative 
mutant while WT TAK1 rescued the ability of P19CL6noggin cell to generate 
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cardiomyocytes. These results indicate that TAK1 play an important role in the control of 
cardiac development [87]. 
 
     1.1.3.5.2. The role of TAK1 in TGF-β signaling pathway.  TAK1 was originally 
identified as a transforming growth factor (TGF)-β-activated kinase. TAK1 activated 
transcription of the reporter gene driven by the PAI-1 gene promoter. Dominant negative 
TAK1 mutant blocked this reporter gene activity induced by TGF-β stimulation [75]. These 
results demonstrated that TAK1 may be involved in the TGF-β signaling pathway.  
Subsequent studies demonstrated that TAK1 was also required for NF-κB activation induced 
by TNF-α and IL-1β.  
 
      1.1.3.5.3. The role of TAK1 in the innate immunity.  It was well established that TRAF 
family members including TRAF2, TRAF5, TRAF6 are required for NF-κB activation 
induced by TNF-α and IL-1β [88].  However, the mechanism how IKKβ is activated was 
unclear.  Both IKK and JNK activation were inhibited by TAK1 specific inhibitor, [89]. The 
activation of IKK and JNK by TNF-α and IL-1β was reduced by the knock down of TAK1 
[90]. These results strongly supported that TAK1 is involved in NF-κB signaling pathway 
activated by TNF-α and IL-1β.  
 
      A kinase complex consisting of three proteins TAK1, TAB1 and TAB2 was purified and 
identified by the biochemical approach. In vitro reconstitution revealed that IKK and MKK6 
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were phosphorylated by TAK1 in an E1, E2 (Ubc13-Uev1A) and E3 (TRAF6) dependent 
manner. Moreover, K63-linked polyubiquitination of TRAF6 was required and sufficient for 
TAK1 activation [91].  
 
Figure 4. The central role of ubiquitin and TAK1 in multiple NF-κB signaling pathways. 
Cell Death and differentiation (2006) 13,687-692. Reprinted by permission from Nature 
publishing group.  
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           1.1.3.5.4. TAK1 knockout mice. Several groups knocked out TAK1 independently 
and the genetic evidence demonstrated that TAK1 is necessary for the signaling pathway 
induced by TNF-α and IL-1β. Sato and colleagues used cre-loxP system to delete exon 2 of 
mouse TAK1, which encodes the ATP binding domain (K63). Deletion of TAK1 in the germ 
line resulted in embryonic death at E10.5. NF-κB, JNK and p38 activation by TNF-α and IL-
1β null MEF cells was impaired. IL-6 production by IL-1β stimulation was reduced and cell 
death was induced by TNF-α treatment. IκBα protein degradation and NF-κB DNA binding 
activity were also impaired in TAK1 knock out MEF cells. B cell–specific TAK1 deletion 
caused the defect in the development of B-1 B cells. Cell cycles into S phase in response to 
LPS and/or CpG DNA were compromised in TAK1 null B cells. B cell antigen receptor 
(BCR) was reduced.  However, JNK, but not NF-κB, p38 or Erk was affected by BCR 
stimulation. Therefore, TAK1 is required for JNK signaling pathway induced by different 
stimuli while NF-κB activation by TAK1 depends on the specific stimuli. TAK1 is also 
required for adaptive immunity response. The production of antigen-specific IgG1 is 
significantly reduced in TAK1 heterozygous mice [92]. 
 
      The second group used gene trap approach to disrupt TAK1 function in mice. The gene 
trap construct contains 2 genes:   a fusion protein (βgeo), which is composed of β-
galactosidase and neomycin phosphotransferase, and human placental alkaline phosphatase 
(PLAP).  This construct was inserted into the first intron to disrupt TAK1 expression. The 
mutant embryos exhibited the developmental defects in head and neural tube at E10 and 
E10.5 and were dead at E11.5. NF-κB and AP-1 responsive promoter activity, IκBα 
degradation, JNK phosphorylation, C-jun phosphorylation and nuclear translocation and  NF-
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κB DNA binding activity all severe  impaired In TAK1 mutant cells stimulated with TNF-α 
and IL-1.  TNF-α treatment induced apoptosis in TAK1 mutant cells, as shown by Annexin-
V and PI staining, and pro Caspase 8 cleavage. In vitro kinase assay showed that TAK1 is 
essential for IKK activity induced by TNF-α and IL-1. However, TAK1 was not involved in 
the alternative NF-κB pathway activated by LT-β, BAFF, and CD40. Luciferase reporter 
gene assay also indicated that TAK1 is required for JNK phosphorylation, NF-κB and AP-1 
activation induced by TGF-β [93].  
 
      Another group used the exact same ES cells containing the insertion in the first intron of 
the TAK1 gene to produce TAK1 mutant mouse. All TAK1 mutant embryos were dead at 
E11.5 as described previously. In addition, the defect in heart development was identified in 
TAK1 mutant mice,   which was omitted by the above report. The TAK1 mutant embryos 
showed defective angiogenesis and the abnormal vascular architecture [84].  
 
      The fourth group used a different knockout strategy to abolish TAK1. Both sides of the 
first exon were flanked by LoxP site. Subsequently, TAK1 flox/flox mice were crossed with 
the Lck-Cre transgenic mice line in which the Cre recombinase was driven by the T cell-
specific Lck to generate the deletion of TAK1 in T cells. T cells percentage in the peripheral 
lymphoid organs was significantly reduced up to 25%. CD4+ or CD8+ single positive 
thymocytes were much less in TAK1 conditional knockout mice than the flox mice. These 
result demonstrated that TAK1 is required for T cell development and maturation. Anti-CD3ε 
stimulation induced the significant increase in apoptosis of CD4+ and CD8+SP thymocytes 
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lacking of TAK1. The degradation of IκBα protein, IKK kinase activity, NF-κB DNA-
binding activity and JNK phosphorylation were severely blocked in thymocytes of TAK1 
conditional knockout mice. These data indicated that TAK1 is essential for NF-κB and JNK 
activation in thymocytes [94]. TAK1 knockout also resulted in the loss of the 
phosphorylation of AMPK at T172, which blocked AMPK activity [95].  In BMP signaling 
pathway, TAK1 was recruited to X-linked inhibitor of apoptosis protein (XIAP) mediated by 
TAB1 upon BMP2/7 stimulation and thereby regulated Smad1/5/8 phosphorylation  [96] . 
 
      1.1.3.6. TAK1 in human. The four splicing variants of TAK1 have been identified in 
human. TAK1b is the full length form which contains 17 exons. TAK1a, which was studied 
most intensively, lacks exon 12. TAK1 c contains no exon 16, which resulted in a reading 
frame shift and therefore produced a shorter protein with the earlier stop codon at the c-
terminal. TAK1 d contains neither exon 12 nor exon16. These four different isoforms 







Figure 5. Schematics of TAK1 mRNA splice variants and the protein isoforms. TAK1a 
and TAK1d lack exon 12; TAK1c and TAK1d lack exon 16. The reading frame shift occurs 
at the 3’ end of the coding sequences of TAK1c and TAK1d due to the lack of exon 16. 





      Most of studies about TAK1 function in human were carried out by transfection 
experiments. It has been demonstrated that TAK1 is required for the activation of SAPK/JNK 
induced by ceramide in COS7 cells [99].  TAK1 also mediated JNK activity stimulated by 
TGF-β in the transient transfections of 293T cells[100]. Cotransfection of TAK1 and TAB1 
stimulated IKK activity and NF-κB activations in HeLa cells [101]. TAK1 mediated also NF-
κB activation induced by Nontypeable Haemophilus influenzae (NTHi) in epithelial cells 
[102]. TAK1 is required for protection from apoptosis induced by TNF-α and interleukin-1b 
converting enzyme (ICE; caspase 1) [103].  
 
      1.1.3.7. TAK1 and cancer. TAK1 play a key role in cancer development of mice. It has 
been reported that TAK1 regulate phosphorylation of JNK and p38 and therefore induced 
pulmonary metastasis in murine cancer colon cells 26 [104]. The inhibition of TAK1 with 
siRNA and the selective inhibitor 5Z-7-oxozeaenol increased in apoptosis induced by tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) in HeLa cells and 
human lung adenocarcinoma A549 cells [105]. 
 
      TNF-induced JNK activation mediated by TAK1 played a role in antiapoptotic effect in 
hepatoma [106]. However, the role of TAK1 in survival is controversial.  It has been reported 
that transfection of TAK1 into human prostate cancer PC-3U resulted in apoptosis [107]. 
TAK was essential for adhesion of the metastatic human breast carcinoma cells (MDA-MB-
435) to the extracellular matrix [108]. It was found that TAK interacted with Epstein-Barr 
virus (EBV) latent membrane protein 1 (LMP1) and therefore activate JNK pathway required 
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for LMP1 oncogenic activity [109]. NF-κB activation in head and neck squamous cell 
carcinoma (HNSCC) was blocked by TAK1 dominant mutant [110].  TAK1 plays a role in 
tumor invasion and metastasis. The inhibition of TAK1 by siRNA or the dominant negative 
mutant repressed the expression of matrix metalloproteinase-9 in the metastatic breast cancer 
cell line and thereby reduced tumor angiogenesis and metastasis in orthotopic xenograft 
model [111]. The oncoprotein induced constitutively NF-κB activation in HCT116 colon 
cancer, HeLa cervical cancer cells, human ZR-75-1, MCF-7 breast cancer cells and MCF-
10A cells.  Phosphorylation of IKK and IκBα induced by TNF-α is blocked by TAK1 siRNA 
in MCF-10A cells [112].  Introduction of dominant negative mutant into MCF10A-CA1a 
cells reduced proliferation and invasion [113]. TAK1 is also required for AMPK activation 
and autophagy pathway induced by TRAIL-R2 in MCF10A cells [114]. 
 
      TAK1 functions not only in NF-κB signaling pathway, but also in EGFR signaling 
pathway. It has been reported that TAK1 is necessary for TNF-α-induced phosphorylation of 
EGFR and internalization and these results implicated that the antiapoptotic effects of EGFR 
induced by TNF- α may be mediated by TAK1 [115]. 
 
      The SnoN is an oncoprotein which inhibits the expression of TGF-β-responsive genes. 
The SnoN is phosphorylated by TAK1 upon TGF-β stimulation and thereby degraded to 
allow the expression of downstream genes through smad activation in HeLa S3 cells [116].   
The Tax oncoprotein encoded by of human T-cell leukemia retrovirus type I (HTLV-
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I) constitutively activate IKK and NF-κB through TAK1 and IKK association. The loss of 
TAK1 blocks NF-κB activation induced by Tax in MEF cells [117]. 
 
      However, the oncogenic effect of TAK1 is controversial. TAK1 was involved with the 
recruitment of histone deacetylase (HADC) to the transcriptional factor Sp1 and thereby 
impaired the expression of the human telomerase reverse transcriptase (hTERT) gene [118] 
in human lung adenocarcinoma cell line, A549 cells. TAK1-P38 is required for the 
phosphorylation and internalization of epidermal growth factor receptor (EGFR) EGFR 
induced by TNF-α. This modification repressed the intercellular tyrosine kinase activity of 
EGFR induced by EGF ligand binding in HeLa cells [119].  
 
      Mutations of the receptor tyrosine kinase Ror2 are associated with Robinow Syndrome. 
The c-terminal domain of the tyrosine kinase receptor Ror2 was phosphorylated by TAK1 in 
the presence of an extracellular wnt ligand binding and thereby regulated Wnt-β-catenin-
LEF/TCF pathway [120]. TAK1 also controlled the expression of cytokines IL-8, TNF-α, 
MIP-1α, and MIP-1β. The cytokine production was significantly reduced by TAK1 selective 
inhibitor 5z-7-oxozeaenol in human neutrophils [121].  The inhibition of TAK1 using RNAi 
repressed the expression of cyclooxigenase-2 (COX-2) induced by collagen-II-dependent in 
primary human chondrocytes (PHCs). These results supported that TAK1 may be used as a 
therapeutic target for osteoarthritis [122].  Etoposide (VP16) is a DNA double-strand break 
(DSB) agent which leads to NF-κB activation in an ATM-dependent manner. TAK1 is 
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required for IKK and NF-κB activation by DNA damage in response to genotoxic stimuli 
[123]. 
 
      As summary, transforming growth factor beta activated kinase 1 (TAK1), known as 
Mitogen-activated protein kinase kinase kinase 7 (MEKK7), is a member of MAP 3 kinase 
family. TAK1 regulates multiple cellular processes. The yeast two hybrid experiments have 
identified TAK1 binding protein 1 and 2, named TAB1 and TAB2, which interact with 
TAK1 [124]. TAK1 plays a key role in both TNFα and IL-1β pathway. Knock down of 
TAK1 RNAi impaired the activation of IKK and JNK by TNFα and IL-1β [90, 125]. The 
inhibitor of TAK1, 5Z-7-oxozeaenol suppress kinase activity of TAK1, resulting in inhibition 
of JNK/p38 MAPK, IκB kinases, and NF-κB [89]. The genetic evidence revealed that knock 
out of TAK1 is embryonic lethal. NF-κB activation induced by TNFα and IL-1β are severely 
impaired in TAK1 knock out MEF cells [92]. co-transfection of TAK1 with its activator 
TAB1 leads to the enhanced migration to fibronectin in vitro and metastasis to the lung in 
vivo [104]. However, what role TAK1 plays in pancreatic cancer and how it is regulate 
remain to be determined. 
 
      1.1.3.8. Proposed model for the regulation of TAK1 in pancreatic cancer. NF-B is 
constitutively activated in the most pancreatic cancer cell lines and tissues. Inhibition of 
constitutive NF-B activity by Ibα mutant suppresses tumorigenesis [58, 59].  It has been 
demonstrated that the autocrine mechanism of IL-1α accounts for the constitutive activation 
of NF-B in metastatic human pancreatic cancer cell lines[126].  TAK1 acts as the upstream 
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of NF-B signaling pathway and it is required for NF-B activation. Therefore, it is 
reasonable to propose that TAK1 plays a role in pancreatic cancer tumorigenesis and 












































Figure 6.  Proposed model for the regulation of TAK1 in pancreatic cancer. This model 
demonstrates that TAK1 may play a key role of survival, antiapoptosis and drug resistance in 





1.2. Materials and method 
 
1.2.1. Cell Lines, antibodies and Reagents 
 
      AsPc-1, PANC-1, BxPc-3, and CFPAC-1 human pancreatic cancer cell lines were 
purchased from the American Type Culture Collection (Manassas, VA). MDAPanc-28 and 
Panc-48 cell lines were obtained from the laboratory of Drs. Marsha L. Fraizer and Douglas 
B. Evans. The Colo357FG cell line was obtained from the laboratory of Dr. Isaiah J. Fidler.  
Human papillomavirus type 16 early gene 6 and 7-immortalized/nontumorigenic human 
pancreatic ductal epithelial (HPDE) cells have been described previously [127]. All cell lines 
used in this study were authenticated using DNA fingerprinting at the genomic core facility 
at Wayne State University (2009) and maintained as described previously [128]. The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, 
MO) assay was used to obtain relative variable cell numbers. 
 
      TAK1, TAB1, Phospho-TAK1 (Thr184/187), IKKβ, Phospho-IKKα/β and Caspase-3 
antibodies were purchased from Cell Signaling Technology, Inc. (#4505, #3225, #4531, 
#2684, #2687, and #9632); Histone H1 antibody was purchased from Santa Cruz 
biotechnology, Inc. (sc-8030). Monoclonal ANTI-FLAG® M2-Peroxidase (HRP) antibody 




      Gemcitabine (Gemzar, Eli Lilly) and oxaliplatin (Eloxatin, Sanofi-Aventis) were 
purchased as lyophilized products, which were then dissolved in sterile saline or 5% dextrose 
solution, respectively. LYTAK1 is an orally active TAK1 kinase-selective inhibitor (TAK1 
Ki = 13 nM; p38 Ki > 20 mM; IKK-β Ki > 20 mM) generously provided by (Cancer Cell 
Biology, Lilly Research Laboratories, 893 South Delaware Street, 48A/4103, DC0546 
Indianapolis, IN 46285). For in vitro assays, LYTAK1 was dissolved in 100% dimethyl 
sulfoxide (DMSO) at a stock concentration of 1 mM. The concentration of DMSO did not 
exceed 0.1% in any assay.  
 
1.2.2. Plasmid and site-directed mutagenesis 
 
      To generate TAK1 sh RNA plasmids, two human TAK1 shRNA target sequences were 
chosen: 5’GAGGAAAGCGTTTATTGTATT3’ and 5’CCCAATGGCTTATCTTACATT3’. 
These sequences were cloned into an FG12 lentivirus vector (gift from Dr. Qin Xiaofeng, 
The University of Texas M. D. Anderson Cancer Center, Houston, Texas) with Bam HI and 
Hind III.  
 
To make “plenti-xia” vector, the multicloning site within pBluescript-KS was dropped 
with Bam HI and XhoI and cloned into Plenti6/v5.. WT-TAK1 tagged with myc was dropped 
from PRK6-MYC-TAK1 (gift from Dr. Xin Lin, The University of Texas M. D. Anderson 
Cancer Center, Houston, Texas) with CLA I and ECORI. The insert was blunted with 
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Klenow and cloned into plenti-xia vector opened with ECOR V. TAK1 kinase dead dominant 
negative mutant tagged with Flag was dropped from PC DNA3.1 Flag-TAK1 (k63A) (gift 
from Dr. Xin Lin, The University of Texas M. D. Anderson Cancer Center, Houston, Texas ) 
with Xba I and Pme I. The insert was blunted with Klenow and cloned into plenti-xia vector 
opened with ECOR V, too. 
 
1.2.3. Generating TAK1 Knockdown Cell Lines and TAK1 dominant negative mutant 
cell lines and TAB1 Knockdown Cell Lines 
 
      Lentiviruses were produced with the third generation packaging system plasmids 
pMDLg/pRRE, pRSV-Rev, and pMD2.G into 293T cells [129]. The virus-containing 
supernatants were collected after 72 hours of transfection and filtered through a Mini-pore 
0.45 μm filtered. The AsPc-1, PANC-1, and MDAPanc-28 cells were transduced by the 
lentivirus in the presence of the polycation Polybrene, and the stably transduced cells were 
then sorted by GFP activity. AsPc-1, PANC-1, and MDAPanc-28 cell lines expressing TAK1 
K63A mutant were produced by the same method and selected with blasticidine. 
 
      TAK1 shRNA rescue experiments were performed stably co-expressing by lentiviral 




TAB1 knocking down constructs were obtained from Open Biosystems.  pMD2.G and 
psPAX2 system are used for packaging 
 
1.2.4. Western Blot Analysis 
 
      Human pancreatic cancer cells and HPDE were washed twice with cold phosphate-
buffered saline and lysed into cold radioimmunoprecipitation assay buffer (50 mM Tris HCl 
[pH 8], 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium 
dodecyl sulfate). Each lysate (20 µg of protein) was separated by 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and probed with a rabbit polyclonal antibody 
against TAK1 (#4505, Cell Signaling Technology, Inc.) and TAB1 (#3225, Cell Signaling 
Technology, Inc.).  For immunoprecipitation experiments, whole-cell lysates were prepared 
with lysis buffer (50mM Tris pH 7.9, 0.5mM EDTA, 150mM NaCl, 5% glycerol, 0.5% NP-
40, 1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride, 1 mmol/L 
phenylmethylsulfonyl fluoride, 1 mmol/L DTT, 10 μg/mL aprotinin, 10 μg/mL leupeptin). 2 
mg cell lysates were immunoprecipitated with 10 μL rabbit anti-TAK1 antibody  (Bethyl 
Laboratories  A301-915A) at 4°C under rotary agitation for 4 hours and then the 
immunocomplexes were captured by 40 μL protein A/ G agarose/sepharose bead slurry 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 4°C for 2 h. The agarose/sepharose 
beads were collected by centrifugation and washed three times with cold lysis buffer. The 
agarose/sepharose beads were boiled in 3x sample buffer for 5 minutes. Each lysate (20 µL 
of protein) was separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
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and probed with a rabbit polyclonal antibody against phospho-TAK1 (#4531, Cell Signaling 
Technology, Inc.). Immunoreactive proteins were visualized with Lumi-Light Western 
blotting substrate (Roche, Indianapolis, IN) according to the manufacturer’s instructions. 
 
1.2.5. Electrophoretic Mobility Shift Assay (EMSA) 
 
      The nuclear extracts were prepared according to the method description before [130]. 
Briefly, cells were washed with cold PBS and lysed into cold buffer A (10 mM HEPES–
KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM 
phenylmethylsulfonyl fluoride) in the first step. The crude cellular lysate was centrifuged, 
and the supernatant was taken of as the cytosolic fraction. The pellet was incubated the cold 
high salt buffer C (20 mM HEPES–KOH pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride) to 
extract nuclear fraction. 
 
       DNA binding assays for NF-B proteins were carried out using 10 μg of nuclear extracts 
as described by Chiao et al [131]. The wild-type double-stranded oligonucleotides containing 
the κB site (5'-AGT TGA GGG GAC TTT CCC AGG C-3') and mutant site (5'-AGT TGA 
GGG GAC TTT CCC AGG C-3' ) were obtained from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA) and labeled with 32P to be used as probes. The reactions were resolved on 
4% polyacrylamide gels with 0.25 X TBE (Tris/Borate/EDTA) running buffer. 
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1.2.6. NF-B reporter gene assay 
 
      The reporter gene luciferase  assay has been described previously [132]. Briefly, one 
microgram each of the wild-type B, reporter plasmids containing the firefly luciferase 
reporter gene and the pRL-TK plasmid, containing the Renilla luciferase gene under the 
control of the herpes simplex virus thymidine kinase promoter as an internal control, was 
cotransfected into cells in triplicate by the lipotransfection method (FuGENE 6; Roche, 
Indianapolis, Ind.) following the manufacturer's instruction. The activities of both firefly and 
Renilla luciferases were determined 48 h after transfection with the dual luciferase reporter 
assay system (Promega, Madison, Wis.). The luciferase activities were normalized to the 




      The extent of apoptosis was analyzed  by DNA fragmentation as previously described in 
[133]. 
 




      Invasion assay was performed in 24-well plates by using a BD Biocoat growth factor-
reduced Matrigel invasion chamber (BD Biosciences) with an 8.0-μm pore size PET 
membrane. Each membrane had a thin layer of GFR Matrigel Basement Membrane Matrix, 
which serves as a reconstituted basement membrane in vitro. The inserts were rehydrated by 
adding 0.5 ml of warm culture medium at 37 °C to the inserts for 2 h. Invasion of pancreatic 
cancer cells expression TAK1 shRNA or TAK1 dominant negative mutant was determined 
and pancreatic cancer cells expression scramble shRNA or empty vectors were used as the 
control. These cells, kept in SFM without growth factors for 24 h, were seeded (5 × 104 cells 
in 0.5 ml of SFM) to the invasion chambers with or without KGF (100 ng/ml) and heparin 
(29.4 μg/ml), and 750 μl of complete keratinocyte-SFM was added to the lower well of the 
invasion plate. Cells were incubated at 37 °C in a humidified atmosphere of 95% air and 5% 
CO2 for 48 h. Noninvading cells from the interior of the inserts were removed by using 
cotton-tipped swabs. Invading cells on the bottom side of the membrane were fixed by 10% 
formaldehyde for 10 min, and then stained with 1% crystal violet, and at least three random 
fields per insert were counted under an Olympus microscope. A representative field of each 
experiment was photographed with 4× lens and 2.5× magnification. Results are shown as the 
means ± S.E. of three independent experiments.  
 
      Migration assay was performed in 24-well plates by using Falcon cell culture inserts, 
which have a PET membrane with 1 × 105 8.0-μm pores per cm2 (BD Biosciences 
Labware). Before the assay was run, HPDE cells were starved for 24 h, and 700 μl of 
complete keratinocyte-SFM was added to the lower well of the migration plate. The cells (5 
× 104 cells/0.3 ml) were seeded to the insert in keratinocyte-SFM with or without KGF (100 
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ng/ml) and heparin (29 μg/ml). The incubation, staining, counting, and photographing 
procedures were the same as for the invasion assay. The representative fields of each 
experiment are shown. Results are shown as the means ± S.E. of three independent 
experiments.  
 
1.2.9. RT PCR 
   
      The PCR was performed as follows: 940C for 5 min, 35 cycles at 940C for 30 s, 550C for 
1 min, and 720C for 1min, and extension at 720C for 7 min. GAPDH was used as the internal 
control. To distinguish TAK1 isoform A and B, the forward primer 5’: 
ACCTCTGAGGGCAAG AGGA3’ and the reverse primer 5’GCTTTTCTGAGGTTGGTCC 
3’ are used to amplify the fragment of TAK1 covering exon 12. 
 
1.2.10. SYBR green quantitative real-time PCR 
 
      PCR primers were synthesized by Sigma. The SYBR green real-time PCR was performed 
using Stratagenen Mx4000TM multiplex quantitative PCR system (La Jolla, CA) with 
Brilliant SYBR green QPCR Master mix (Stratagene, La Jolla, CA) according the 
manufacturer’s instructions. Real-time PCR was performed in a total volume of 25 μl using 1 
μl of the first-strand cDNA synthesis mixture as the template. 2.5 pmol primer was used for 
each reaction. The PCR was performed as follows: 940C for 5 min, 35 cycles at 940C for 30 
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s, 550C for 1 min, and 720C for 1min, and extension at 720C for 7 min. GAPDH was used as 
the internal control to normalize the expression level. The relative quantification of gene 
expression level was determined by the comparative CT method (2−ΔΔCT). 
 
1.2.11. MTT assay 
 
      1,000 cells per well were plated on 96 well plate in triplicate wells, At day1, day2, day3, 
day4, day5, the MTT assay was carried out  by adding 10µl of 5 mg/ml solution of MTT 
(Sigma Chemical Co., St. Louis, MO) to wells and incubating for 4 hours at 370C. The 
supernatant was removed and the blue MTT formazan precipitates was then dissolved in 100 
µl/well of demethyl sulfoxide. The plates were placed on a shaker for 10 minutes at room 
temperature in the dark and absorbance was measured on a plate reader at 570nm. Data were 
shown as the mean value ± standard error of three independent experiments.  Growth curves 
were generated by Excel. 
 
1.2.12. Nude Mouse Orthotopic Xenograft Model 
 
      Six- to 8-week-old female athymic nude mice (NCI-nu) were purchased from the Animal 
Production Area of the National Cancer Institute—Frederick Cancer Research Facility 
(Frederick, MD). All mice were housed and treated in accordance with the guidelines of The 
University of Texas M. D. Anderson Cancer Center’s animal care and use committee, and the 
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mice were maintained in specific pathogen-free conditions. The facilities were approved by 
the Association for Assessment and Accreditation of Laboratory Animal Care and met all 
current regulations and standards of the U.S. Departments of Agriculture and Health and 
Human Services and the National Institutes of Health.  
 
      To produce pancreatic tumors, pancreatic cancer cells including AsPc-1, panc-1 and 
panc-28 with or without TAK1 shRNA or TAK1 dominant negative mutant were harvested 
from subconfluent cultures by brief exposure to 0.05% trypsin and 0.02% EDTA. 
Trypsinization was quenched with medium containing 10% fetal bovine serum, and the cells 
were washed once in serum-free medium and resuspended in serum-free Hanks’ balanced 
salt solution. Only suspensions consisting of single cells with more than 90% viability were 
used for the injections. The orthotopic injection of pancreatic cancer cells was performed as 
described previously [128]. Briefly, the mice were anesthetized with a 1.5% isoflurane–air 
mixture. A small incision was made on the left side of abdominal flank, and then the spleen 
was exteriorized. 1.0 × 106  tumor cells in 50 μL of Hanks’ balanced salt solution were 
injected in a region of the pancreas just beneath the spleen. A 30-gauge needle, 1-mL 
disposable syringe, and calibrated, push button–controlled dispensing device (Hamilton 
Syringe, Reno, NV) were used to inject the tumor cell suspension. A successful subcapsular 
intrapancreatic injection of tumor cells was identified by the appearance of a fluid bleb 
without intraperitoneal (ip) leakage.  To prevent leakage, a cotton swab was used to cover the 
injection site for 1 minute. One layer of the abdominal wound was closed with wound clips 
(Auto-clip; Clay Adams, Parsippany, NJ).  All the animals tolerated the surgical procedure 
well, and there were deaths due to anesthesia. 
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      Eight weeks after injection, mice were dissected and the tumor was removed for 
photographing and measurement. 
 
 
1.2.13. Immunohistochemistry and Tissue Mineral Analysis (TMA) 
 
1. De-paraffin: Incubate the slides at 60°C for 1 hr. 
2. Re-hydrated the tissue: 
    Put the slide in the following solution by order: 
Xylene                 4 min 
Xylene                 3 min 
100%EtOH          1 min 
100%EtOH          1 min 
80%EtOH            1 min 
30% EtOH           1 min 
1X PBS               15 min 
3. Target retrieves the antigen: 
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     Turn on the steamer. Preheat the target retrieval solution (Antigen Unmasking H3300-
Vector) and steamer water in microwave oven, approx. Slides were incubated in hot target 
retrieval solution in the steamer for 15-20 min, and then cool down at RT for 20 min or more. 
4. Immunohistochemistry assay: 
           (1) Wash the slides with PBS 2 X 5 min. 
      (2) Draw a circle along the tissue edge with ImmEdge pen (Vector) to keep the 
solution on the surface of the tissue. Add the Biotin Block solution (Avidin Biotin 
Blocking SP2001, Vector) on the surface of tissue and incubate at RT for 30 min. 
      (3) Wash the slides with PBS 2 X 5 min. 
      (4) Add the protein blocking solution (X0909-Dako) or 0.1 % BSA in PBS on the 
surface of the tissue, incubate at RT for 30 min.  Remove blocking solution. 
     (5) Incubate with primary antibody at 4C overnight. (Antibody concentration depends 
on previous experiment or company information), antibody usually dilutes in 0.1% BSA 
in PBS. 
     (6) Wash the slides with PBS 2 X 5 min. 
     (7) Incubate with biotinylated secondary antibody (Vectastain ABC-peroxidase Kit) at 
RT for 30 min. 
     (8)Wash the slides with PBS 2 X 5 min. 
      (9) Incubate with ABC (from Vectastain ABC kit) reagent at RT for 30 min. 
      (10) Wash the slides with PBS 2 X 5 min. 
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      (11) Use DAB substrate (Sigma #D4168) to develop the color about 2 to 5min, no 
more 10 min. 
      (12) Rinse the slides in tap water. 
      (13) Counterstain the slides with Mayer’s Hematoxylin (Dako #S3309) solution for 10 
min. 
5. De-hydration of the tissue: 
         Put the slides in following solution by order: 
30%EtOH               1 min 
80%EtOH               1 min             
100%EtOH             1 min             
100%EtOH             1 min 
Xylene                    1 min 
Xylene                    2 min 
        
 Air dries the slides and add one drop of Permanent mount medium on the surface of the 
tissue, cover them with the cover-slide. 






1.2.14. Statistical Analysis 
      The results of in vitro proliferation are expressed as means (95% confidence intervals 
[CIs]) for at least three independent experiments performed in triplicate. The statistical 
significance of differences in tumor growth was determined by one-way analysis of variance 
and Dunnett's test; differences in survival duration were determined using a log-rank test. All 
statistical tests were two-sided, and a P value less than 0.05 indicated statistical significance. 
All statistical analyses were performed using GraphPad Prism software version 4.0c 
















1.3.1. TAK1 splicing variants are differentially expressed in pancreatic cancer cells.   
 
      As stated above, TAK1 is an upstream kinase for IKK β which activates NF-B by 
phosphorylation of Ser32, 36 in IB. Four TAK1 alternative splicing variants have been 
identified, called TAK1a, TAK1b, TAK1c, and TAK1d. TAK1b is the longest transcript. 
Compared with TAK1b, TAK1a lacks exon 12, TAK1c lacks exon 16 and TAK1d lacks both 
exon 12 and exon 16. The carboxyl-terminal domain in TAK1c and TAK1d is replaced by a 
truncated sequence generated by translation of the sequence downstream of the alternative 
splice site in another frame due to the lack of exon 16 (Fig.5, [98]. 
 
      However, it was unclear which variant participated in TGF- pathways as it was 
originally discovered as a TGF- activating kinase, which TAK1 variants is required for 
activating NF-B and what function each TAK1 variant has.  To determine the function of 
each TAK1 splicing variant, we reintroduced each of the four splicing variants of TAK1 back 
into TAK1-knockout MEF cells. We measured the NF-B activation using EMSA and found 
that only TAK1a and TAK1b, but not TAK1c and TAK1d, can restore cytokine-induced NF-
B activation (unpublished data). Because exon 16 is missing in TAK1c and TAK1d, these 
results implicate that each of the TAK1 variants may have the distinct role in regulation of 
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cytokine-induced NF-B activation. However, how exon 16 is involved in cytokine-induced 
NF-B activation is still unknown.   
 
      To distinguish the function of TAK1 splicing variants in pancreatic cancer, we isolated 
RNA from two normal pancreatic tissues and four pancreatic tumor tissues. We evaluated the 
expressing lever of the different TAK1 splicing variants in these tissues by RT-PCR. As 
shown in figure 7A, our result demonstrated that the ratio of TAK1a to TAK1a is much 
higher in most pancreatic tumor tissues than in normal pancreatic tissues. To confirm this 
finding, we tested twelve more tissues, which include six normal and six tumor tissues.  Our 
result confirmed the previous finding (figure 7B). DNA sequence data confirmed that the 
lower band lacks the exact exon 12 (Data not shown). Taken together, TAK1 may be 
dysregulated by the alternative splicing in pancreatic cancer. However, what function of each 









Figure 7. Different ratios of the 2 TAK1 mRNA variants expressed in normal 
pancreatic tissues and pancreatic tumor tissues. RT-PCR were carried out with RNAs 
isolated from six normal pancreatic tissues and six pancreatic tumor tissues. TAK1 primers 







1.3.2. TAK1 and TAB1 are overexpressed in pancreatic cancer cells; NF-B is activated 
in pancreatic cancer cell lines. 
 
       To study the role of TAK1 in pancreatic cancer chemoresistance, we initially evaluated 
the expression levels of TAK1 and TAK1 binding protein TAB1 in twelve different 
pancreatic cancer cell lines and in the immortalized and nontumorigenic E6E7 cell line, 
demonstrating the overexpression of TAK1 and TAB1 in most of the malignant cell lines 
compared with the nontumorigenic control (Fig.8A).  
 
      NF-B activity was analyzed by electrophoresis mobility shift assay. Consistent with the 
previous report [58, 59], NF-B is highly activated in most of pancreatic cancer cells 
(Fig.8B). These data support that NF-B play a role in pancreatic cancer.  More importantly, 
NF-B activity is also highly correlated with the expression levels of TAK1 and TAB1.  For 
example, the expression levels of TAK1 and TAB1 and NF-B activity are lower in BxPc-3 
and Miapaca-2 than in most of other cell lines. This data support that TAK1 and TAB1 may 
contribute to NF-B activation in pancreatic cancer cell lines. 
 
      We also examined TAK1 expression in mouse pancreatic tumor tissue using 
immunohistochemistry staining with anti-TAK1. Our data demonstrated that the expression 














Figure 8.  TAK1 and TAB1 are overexpressed in pancreatic cancer. A.TAK1 and TAB1 
are overexpressed in pancreatic cancer cell lines. Protein extracts were analyzed on 
Western blot (50g/of protein extract/lane) and probed with the indicated antibodies. 
Cytoplasm fraction extracted from the normal cell line (lane1) and twelve tumor cell lines 
(lane2 through 13).  E6E7 is immortalized but not transformed epithelial cells and was used 
as a normal control. β-actin was used as the loading control. B. NF-κB activity is activated 
in most of pancreatic cancer cell lines. EMSA was performed to determine the NF-κB 
activity in E7E7 and twelve pancreatic cancer cell lines as indicated.  Histone H1 was 
determined as loading controls.  C. TAK1 is overexpressed in human pancreatic tumor 
tissue. Immunohistochemistry staining was performed for mouse pancreatic tumor and 




1.3.3. The expression levels of TAK1 and TAB1 are highly correlated in pancreatic 
cancer cell lines and human tumor tissues. 
 
      It has been demonstrated that TAB1 interacts with TAK1 and enhance TAK1 activity 
[124]. Interestingly, the expression levels of TAK1 and TAB1 are highly correlated in 
pancreatic cancer cell lines (Fig. 8A). For instance, both TAK1 and TAB1 are expressed at a 
high level in most of cell lines such as AsPc-1, Capan-1, CFPAC-1, Hs766T, and L3.6 but at 
a low level in the other cell lines such as BxPc-3 and Miapaca-2.  
 
      We also analyzed patient tumor tissue using immunohistochemistry staining with TAK1 
and TAB1 antibodies. As shown in Fig. 9A, TAK1 and TAB1 were majorly expressed in 
pancreatic ductal cells. More than 100 hundred tumor samples were analyzed with tissue 
microarray. We classified TAK1 and TAB1 expression level into two levels for χ2 test.  The 
statistics with a large χ2=180 demonstrated that TAK1 and TAB1 is highly associated with 
each other (Fig. 9B). These results strongly implicate that TAK1 may be regulated by TAB1 
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Figure 9.  The expression of TAK1 and TAB1 are correlated in human pancreatic 
cancer tissue. A. Expression of TAK1 in human pancreatic cancer or normal tissue was 
analyzed by immunohistochemical staining. B. Expression of TAB1 in human pancreatic 
cancer or normal tissue was analyzed by immunohistochemical staining. C. TAK1 and TAB1 
expression were classified into four levels. Tissue microarray analysis was summarized in the 
4 X4 table.  χ2 test was used to determine the association of TAK1 and TAB1. D. The 




1.3.4. TAK1 Silencing in Pancreatic Cancer Cells. 
 
      TAK1 plays a key role in the cellular processes of infection, inflammation. TAK1 is 
necessary for the activation of NF-κB in response to stimulation by proinflammatory 
cytokines such as TNF-α and IL-1β. NF-B activation is severely impaired in TAK1-null 
MEF cells [92].  The study has shown that TAK1 acts as an upstream activating kinase for 
IKKβ Phosphorylation of IKKβ leads to the activation of IKK. TAK1 can also phosphorylate 
and activate MKK6 and MKK7, therefore activate p38 and JNK kinase pathways[91]. NF-B 
is constitutively activated in most pancreatic cancer cells [58].  To determine the role of 
TAK1 in pancreatic cancer, we knocked down the expression of TAK1 in pancreatic cancer 
cell lines. Firstly, we tested effect of target sequences on RNAi efficiency for TAK1 in 293T 
cells using siRNA. As shown in Fig. 10 A., both siRNAs have significant knock down of 
TAK1 in 293T cells. Because the efficiency of transient transfection of siRNA into 
pancreatic cancer cells is very low, we generated constructs expressing shRNA of TAK1 
using the lentivirus vector FG12 that contains the GFP selective marker. High infection 
efficiencies of the siRNA in AsPC-1, BxPc3, PANC-1, and PANC28 cells were yielded.  
 
      We used two pooled shRNA sequences to knock down the expression of TAK1 in three 
different pancreatic cancer cell lines, AsPc-1, PANC-1, and MDAPanc-28. These cell lines 
were transduced with lentiviruses expressing TAK1-specific shRNAs or a scramble sequence. 
With this approach, we were able to significantly reduce the expression of TAK1 in the cell 










Figure 10. The effects of TAK1shRNA on pancreatic cancer cell lines. A. Testing TAK1 
knocking down effects in 293T cells.  Transfection of siRNA effectively knocked down the 
expression of TAK1 in 293T cells.   B.TAK1 shRNA is infected into of TAK1 in AsPc-1, 
PANC-1, and MDAPanc-28 pancreatic cancer cells by lentivirus.  Protein extracts from these 
pancreatic cancer cell lines with or without infection were analyzed on Western blot (50g/of 







1.3.5. Silencing TAK1 Suppresses NF-B DNA Binding Activities. 
 
      TAK1 has been identified as an IKK kinase in TNF-α and IL-1 signaling pathway, which 
contributes to of NF-B activation [91].  We analyzed NF-B activity in the pancreatic 
cancer cell lines using different approaches.  Luciferase assay demonstrated that whereas 
AsPc-1 and MDAPanc-28 TAK1 knockdown cells had a very low NF-B activity, the same 
cells stably expressing wild-type murine TAK1 demonstrated an NF-B activity similar to 
the control cell lines (Fig. 11). Knocking down the expression of TAK1 suppressed the 
autophosphorylation of residual TAK1 proteins (Fig.12), and reduced the phosphorylation of 
p38, a downstream target of the TAK1-MKK6 intracellular pathway [102] (Fig.13). 
 
      To determine the effect of silencing TAK1 on the constitutive activation of NF-B, we 
also evaluated IKK kinase activity and the DNA binding activity of NF-B transcriptional 
factor in knockdown and control cell lines. We demonstrated that knocking down the 
expression of TAK1 dramatically suppresses IKK phosphorylation (Fig.14 A) and the DNA-
binding activity of NF-B (Fig.14B) and in the pancreatic cancer cell lines compared with 
the respective controls.  
 
      Taken together, these data demonstrate that TAK1 is an essential mediator of the 






Figure 11. TNF-κB activation is reduced in TAK1 knocking down cells. TAK1 shRNA 
rescue experiment. Nuclear factor κB (NF-κB) reporter gene assay in AsPc-1 and MDAPanc-
28 cells transduced with lentiviruses expressing TAK1-specific shRNA, a scramble sequence, 
or stably coexpressing human TAK1 shRNA and wild-type murine TAK1 sequences. The 
luciferase activities were normalized to the Renilla luciferase activity of the internal 
control. Error bars indicate 95% confidence intervals of two independent experiments 
performed in triplicate. Asterisks indicate statistical significance (P < .001) compared with 








Figure 12. TAK1 kinase activity is reduced in TAK1 knock down cells.  Western blot 
analysis for the autophosphorylation of TAK1 in AsPc-1, PANC-1, and MDAPanc-28 
pancreatic cancer cells transduced with lentiviruses expressing TAK1-specific shRNA or a 








Figure 13.  P38 kinase activity is reduced in TAK1 knock down cells.   Western blot 
analysis for the phosphorylation of p38 in AsPc-1, PANC-1, and MDAPanc-28 pancreatic 
cancer cells transduced with lentiviruses expressing TAK1-specific shRNA or a scramble 











Figure 14. TAK1 is required for IKKα/β phosphorylation and NF-κB activation in 
pancreatic cancer cells. A. Western blot analysis for the phosphorylation of IKKα/β in 
AsPc-1 and MDAPanc-28 pancreatic cancer cells transduced with lentiviruses expressing 
TAK1-specific shRNA or a scramble sequence as control.  Total IKKα/β was used as loading 
control. EMSA was performed to determine the NF-κB activity in pancreatic cancer cell line 





1.3.6. Silencing TAK1 Induces a Potent in Vitro Chemosensitization and apoptosis of 
Pancreatic Cancer cells. 
 
      It is well known that pancreatic cancer is extremely resistance to chemotherapeutical 
drugs. To test our hypothesis that TAK1 would be responsible for the chemoresistance of 
pancreatic cancer, we determined the sensitivity of the TAK1 knockdown and control cell 
lines to three chemotherapeutic agents with different mechanisms of action that are either 
currently used or recently studied in combination with gemcitabine for pancreatic cancer 
treatment: DNA-intercalating agent oxaliplatin, topoisomerase I inhibitor SN-38, and 
nucleoside analog gemcitabine. AsPc-1, PANC-1, and MDAPanc-28 TAK1 knockdown cells 
demonstrated a significantly higher sensitivity to these chemotherapeutic agents than did 
their respective control cell lines. As indicated in Fig.15A, with the exception of the already 
gemcitabine-sensitive PANC-1 cells, after knocking down TAK1, we observed a significant 
increase in the sensitivity to gemcitabine for the moderately resistant AsPc-1 and the 
extremely gemcitabine-resistant MDAPanc-28 cells. All three knockdown cell lines were 
significantly more sensitive in the same extent to the irinotecan active metabolite SN-38. A 
dramatic chemosensitization to oxaliplatin was observed in all three knock down cell lines, 




Figure 15. Effects of TAK1 silencing on chemoresistance of pancreatic cancer cells.  A. 
Percent survival of AsPC-1, PANC-1, and MDAPanc-28 pancreatic cancer cells after 
treatment with increasing molar concentrations of gemcitabine, SN-38, and oxaliplatin. 
Dimethyl sulfoxide–treated cells were assigned a value of 100% and designated as control. 
Means and 95% confidence intervals of three independent experiments performed in 




     
 
Figure 15. Effects of TAK1 silencing on chemoresistance of pancreatic cancer cells.  B. 
Percent survival of AsPC-1, PANC-1, and MDAPanc-28 pancreatic cancer cells after 
treatment with increasing molar concentrations of gemcitabine, SN-38, and oxaliplatin. 
Dimethyl sulfoxide–treated cells were assigned a value of 100% and designated as control. 
Means and 95% confidence intervals of three independent experiments performed in 






 Since several studies have shown that the proapoptotic stimuli elicited by the cytotoxic 
agents activate the antiapoptotic function of NF-B [134], we determined the activation of 
NF-B after treatment with IC50 doses of the cytotoxic agents. Whereas the control cells 
already demonstrated substantial activation of NF-B that could not be further augmented by 
exposure to the cytotoxic agents, the TAK1 knockdown cells had much lower levels of NF-
B activation and were unable to increase NF-B activation, even if treated with IC50 doses 
of the cytotoxic agents (Fig.16). In this regard, whereas the control pancreatic cancer cells 
were protected from apoptosis, the TAK1 knockdown cells demonstrated a high induction of 
apoptosis as demonstrated by an increased level of caspase-3 cleavage products (Fig. 17A ) 
and by the fragmentation of genomic DNA (Fig. 17B ).  These data demonstrate that TAK1 





Figure 16. Nuclear factor κB (NF-κB) activation after treatment with cytotoxic agents. 
AsPc-1, PANC-1, and MDAPanc-28 pancreatic cancer cells transduced with lentiviruses 
expressing TGF-β-activated kinase-1 (TAK1)-specific small hairpin RNA (shRNA), or a 
scramble sequence as control were treated for 24 hours with doses of gemcitabine, SN-38, or 
oxaliplatin corresponding with the IC50for the control cells or saline as 
control.  Electrophoretic Mobility Shift Assay analysis was performed to determine the 
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Figure 17. Silencing TAK1 with the treatment of chemotherapeutical drugs induces 
proapoptosis phenotypes. A. Apoptosis of pancreatic cancer cell lines was measured by 
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Figure 17. Silencing TAK1 with the treatment of chemotherapeutical drugs induces 
proapoptosis phenotypes.  B. Apoptosis of pancreatic cancer cell lines was measured by 






1.3.7. TAK is inactivated by the dominant negative mutant form. 
 
      To confirm the results from TAK1 shRNA knocking down, we also inactivate TAK1 
function using the dominant negative mutant, which is the TAK1 kinase dead form in which 
the ATP binding pocket was mutated from lysine to alanine at the amino acid residue 63.  
Using lentivirus transduction, we were able establish the five stable cell lines which 
expressed TAK1 K63A mutant.  As shown in Fig. 18, IKKα/β phosphorylation was 
significantly reduced and NF-B activation was blocked in pancreatic cancer cell line by the 
kinase dead mutant K63A. These results furthermore support that TAK1 play an essential 
















Figure 18. TAK1 activity is inhibited by the dominant negative mutant K63A in 
pancreatic cancer cells. Lentivirus transduction was used to establish stable cell lines as 
indicated which expressed TAK1 kinase dead mutant form K63A. IKKα/β activity was 
analyzed by western blot and NF-κB activation was determined by EMSA. Total IKKα/β and 






1.3.8. The inactivation of TAK1 suppresses pancreatic cancer cell migration and 
invasion. 
 
      The metastatic property of pancreatic cancer is still a big challenge for patients. 
Acquiring the potential of migration and invasion is a prerequisite for cancer metastasis. To 
study the role of TAK 1 in the controlling migration and invasion of pancreatic cancer cells, 
we performed Boyden chamber migration and Matrigel invasion for the TAK1 knocking 
down cells, TAK1 K63A mutant cells and control cells. Our results demonstrated that the 
inactivation of TAK1 with either shRNA or kinase dead mutant significantly reduced the 
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Figure 19. Blocking TAK1 inhibits pancreatic cancer cell migration.  The Chamber 
migration assay was performed to determine the potentials of cell migration. The 
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Figure 20. Blocking TAK1 inhibits pancreatic cancer cell invasion.  The Matrigel 
invasion was performed to determine the potentials of cell invasion. The representative field 




1.3.9. Targeting TAK1 kinase activity chemo sensitizes pancreatic cancer cells In Vitro 
 
      To establish TAK1 as a pharmacologically relevant target for the chemosensitization of 
pancreatic cancer, we firstly tested the activity of the TAK1-kinase selective inhibitor 
LYTAK1 in vitro. Four pancreatic cancer cell lines – AsPc-1, PANC-1, MDAPanc-28, and 
Colo357FG – were exposed for 24 hours to increasing doses of LYTAK1. LYTAK1 had 
potent in vitro cytotoxic activity, demonstrating an IC50 between 5 and 40 nM (Fig.21, A). 
At this dose range, the kinase activity of TAK1 was markedly inhibited as indicated by the 
suppression of the autophosphorylation of TAK1 and the phosphorylation of p38 (Fig.21, B). 
To demonstrate that the inhibition of the kinase activity of TAK1 would suppress the 
activation of NF-B, we studied the effect of LYTAK1 on the DNA binding activity of this 
transcriptional factor. We observed that in the concentration range indicated, LYTAK1 was 
able to completely suppress the constitutive activation of NF-B in the pancreatic cancer cell 




Figure 21. Activity of the TAK1 inhibitor LYTAK1 in vitro.  A. Percent survival of AsPc-
1, PANC-1, MDAPanc-28, and COLO357FG pancreatic cancer cells after treatment with 
increasing molar concentrations (log scale) of LYTAK1. Dimethyl sulfoxide (DMSO)–
treated cells were assigned a value of 100% and designated as control. Means and 95% 
confidence intervals of three independent experiments performed in quadruplicate are shown. 
Curves were fitted by nonlinear regression analysis. B. Western blot analysis was performed 
to determine the expression and phosphorylation of TAK1 and p38, and C.  Electrophoretic 
Mobility Shift Assay analysis was performed to determine the DNA-binding activity of NF-
κB p65/p50 and p50/p50 complexes in AsPc-1, PANC-1, and MDAPanc-28 pancreatic 
cancer cells treated for 24 hours with increasing doses of LYTAK1 or DMSO as control. 
Similar results were obtained with three independent experiments. 
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      To test our hypothesis that the pharmacologic inhibition of TAK1 would modulate the 
chemoresistance of pancreatic cancer, we determined whether the addition of LYTAK1 
resulted in an increased in vitro antitumor activity when combined with classic 
chemotherapeutic agents. AsPc-1, PANC-1, and MDAPanc-28 pancreatic cancer cells, and 
HPDE cells as control were treated with increasing doses of oxaliplatin, SN-38, or 
gemcitabine in combination with LYTAK1 at doses corresponding with the IC50 measured 
for each cell lines, or DMSO as control. The addition of LYTAK1 potentiated the 
cytotoxicity of these chemotherapeutic agents against the three different pancreatic cancer 
cell lines. No further significant sensitization was measured in the HPDE control cells 
(Fig.22). The pharmacologic inhibition of TAK1 induced an increase in the sensitivity of the 
pancreatic cancer cell lines to chemotherapeutic agents to the same extent or, in the most 
resistant lines, considerably better than the sensitivity obtained with the genetic silencing of 
TAK1. 
 
    Taken together, these results indicate that inhibiting TAK1 kinase by LYTAK1 effectively 




Figure 22. Inhibition of TAK1 and chemosensitization of human pancreatic cancer cells 
in vitro.  Percent survival of AsPC-1, PANC-1, and MDAPanc-28 pancreatic cancer cell 
lines, and human papillomavirus type 16 early gene 6- and 7-immortalized/nontumorigenic 
human pancreatic ductal epithelial (HPDE) control cells after treatment with increasing 
molar concentrations (log scale) of gemcitabine, SN-38, and oxaliplatin alone or in 
combination with LYTAK1 at doses corresponding with the IC50 measured for each cell line 
or dimethyl sulfoxide (DMSO) as control. DMSO-treated cells were assigned a value of 100% 
and designated as control. Means and 95% confidence intervals of three independent 
experiments performed in quadruplicate are shown.  
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1.3.10. TAK1 and TAB1 stabilize each other in pancreatic cancer cell line. 
       
      As indicated above, TAK1 plays an important role in chemotherapeutic drug resistance in 
pancreatic cancer cells. Block TAK1 activity can reverse pancreatic cancer cell resistance to 
chemotherapeutic drug.  NF-B signaling pathway activates anti-apoptosis pathway and 
thereby mediates chemotherapeutic drug resistance. However, the underlying mechanism 
how TAK1 is activated in pancreatic cancer cells is still unknown.   As shown above, the 
expression levels of TAK1 and TAB1 are highly correlated in almost all of pancreatic cancer 
cell lines and tumor tissues.  To explore the regulatory mechanism of TAK1, we studied the 
role of TAK1 binding protein 1 (TAB1) in pancreatic cancer cell line. Firstly, we confirmed 
the existence of the interaction between TAK1 and TAB1 in pancreatic cancer cell lines.  As 
shown Fig. 23A, TAK1 can coimunoprecipitate with TAB1 even without any stimulation. 
 
       A lot of experiments have demonstrated that TAK1 is regulated by TAB1 and TAB1 is 
required for TAK1 activity.  However, however, the role of TAB1 in the control of TAK1 
activity is still controversy.  It was reported that IL-1 induced NF-κB activation was not 
affected but IL-1 or TNF-α induced TAK1 activity was severely inhibited in TAB1 deficient 
cells [135].  To clarify the role of TAB1 in pancreatic cancer cells, we silenced TAB1 in the 




      We measure TAB1 level in TAK1 knocking down cells.  Interestingly, TAB1 protein 
level was also decreased in TAK1 knocking down cells while the mRNA level of TAB1 did 
not change (Fig. 23B).  These experiments demonstrated that TAB1 is stabilized by TAK1 at 
protein level but not increased by mRNA transactional level, determined by SYBR green 
quantitative real-time PCR. Conversely, TAK1 protein level was also decreased in TAB1 
knocking down cells while the mRNA level of TAK1 did not change. TAK1 is stabilized by 
TAK1 in Panc-1 cells (Fig. 23C).  .  This mechanism may be common in pancreatic cancer 
cell lines. We also analyzed the effect of TAB1 on NF-B activity. As indicated in Fig. 23D, 
















Figure 23. TAK1 and TAB1 stabilize each other in pancreatic cancer cell line. A. TAK1 
and TAB1 interact with each other in pancreatic cancer cells. TAB1 antibody was used to 
precipitate the protein complex in TAK1 knocking down cells and the control cells as 





































































 Figure 23. TAK1 and TAB1 stabilize each other in pancreatic cancer cell line. B. TAB1 
is stabilized by TAK1 in pancreatic cancer cells.  TAK1 and TAB1 protein levels were 










































Figure 23. TAK1 and TAB1 stabilize each other in pancreatic cancer cell line. C. TAK1 













1.3.11. Silencing TAK1 or TAB1 reduced tumor size in Orthotopic Xenograft models. 
 
      As indicated above, the inactivation of TAK1 suppresses pancreatic cancer cell migration 
and invasion. To test our hypothesis that TAK1 play a role in pancreatic cancer progression, 
we determined if targeting TAK1 or TAB1 could inhibit growth of human pancreatic cancer 
cells in an orthotopic xenograft mouse model. Five mice for each group were orthotopically 
injected with the different pancreatic cancer cell lines as indicated. Eight weeks after 
injection, all mice were sacrificed, and the degrees of tumorigenesis were investigated. 
 
      AsPc-1 and Panc-28 are extremely malignant and aggressive cell lines. As shown in Fig. 
24, the mice injected by the control cells (AsPc-1 or Panc-28) exhibited high tumor burden 
and the inactivation of TAK1 by shRNA or kinase dead mutant significantly reduced tumor 
size.  Interestingly, tumor yield was also decreased in mice injected by TAB1 knocking down 
cells (Fig. 25). These data support that TAK1 and TAB1 play an essential role in 









































































































Figure 24. The inactivation of TAK1 suppresses tumorigenicity in an orthotopic mouse 
model. One million viable cells for each cell line as indicated were suspended in 50 µl 
phosphate-buffered saline (PBS) and injected into the pancreatic parenchyma of female 
athymic BALB/c nude mice at 8 weeks of age (Charles River Laboratories, Inc. Wilmington, 
MA, USA). Eight weeks after injection, all mice were sacrificed, and the degrees of 






































Figure 25. The inactivation of TAB1 suppresses tumorigenicity in an orthotopic mouse 
model. One million viable cells for each cell line as indicated were suspended in 50 µl 
phosphate-buffered saline (PBS) and injected into the pancreatic parenchyma of female 
athymic BALB/c nude mice at 8 weeks of age (Charles River Laboratories, Inc. Wilmington, 
MA, USA). Eight weeks after injection, all mice were sacrificed, and the degrees of 












1.4.1. Targeting TAK1 increased the sensitivity of pancreatic cells to 
chemotherapeutical drugs and blocks tumorigenesis. 
 
      As introduced before, NF-B is constitutively activated in the most pancreatic cancer cell 
lines and tissues. Inhibition of constitutive NF-B activity by Ibα mutant suppresses 
tumorigenesis [58, 59].  The genetic evidence revealed that NF-κB activation induced by 
TNFα and IL-1β are severely impaired in TAK1 knock out MEF cells [92]. Therefore, we 
rationalized that TAK1 plays a role in pancreatic cancer. 
 
      Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United 
States and the fifth leading cause of cancer-related mortality worldwide. According to the 
estimation of the American Cancer Society, approximately 43140 will be diagnosed with this 
cancer and 36800 will die of it in 2010.  Pancreatic cancer is a big challenge in large due to 
the lack of early symptoms. In addition, drug resistance is a major obstacle to the success of 
chemotherapy in pancreatic cancer. The underlying mechanism of drug resistance in human 
pancreatic cancers is not well understood. Better understanding of the mechanism of 
molecular pathways in human pancreatic cancers can help to identify the novel therapeutic 
target candidates, and develop the new preventive and clinic strategies to improve patient 
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survival. We found that TAK1 is overexpressed in most pancreatic cancer cell lines the 
protein plays an important role in the survival of the cells. The goal of this research project is 
to identify novel therapeutic agents that target transforming growth factor beta activated 
kinase 1 (TAK1, MEKK7) in human pancreatic cancer. 
 
      TGF- signaling pathway is frequently defective in various types of cancer such as 
pancreatic and colon cancers.  TGF- legends and their receptors are overexpressed in 
pancreatic cancer cells. TGF- enhances invasion and the epithelial-to-mesenchymal 
transition (EMT). TAK1 is a key component in TGF- signaling pathway. In addition, TAK1 
is required for TNF-α induced and IL-1β induced NF-κB activation. TAK1 plays a key role 
in pro-inflammatory signaling. Chronic or recurrent inflammation contributes to many types 
of cancer. Our lab previous demonstrated that nuclear factor-κB (NF-κB) is constitutively 
activated in most human pancreatic cancer cell lines but not in normal pancreatic tissues. The 
inhibition of the constitutive NF-κB activity in human pancreatic cancer cell lines blocked 
tumorigenesis of pancreatic cancer cells. NF-κB is a key mediator of pancreatic cancer cell 
survival.  Since TAK1 acts as the upstream of NF-κB and it is required for NF-κB activation, 
we propose that TAK1 plays a key role of chemo-drug resistance in pancreatic cancer. In this 





      TAK1 has recently emerged as a central regulator of diverse physiological processes 
including development, metabolism, and immune and stress responses leading to the 
activation of the transcription factors NF-B and AP-1 [136]. To demonstrate an important 
role for TAK1 in cancer, we silenced its expression or inhibited its kinase activity in 
pancreatic cancer cells. Our preliminary results demonstrated that TAK1 is overexpressed in 
most pancreatic cancer cell lines. Knocking down of TAK1 using RNAi technique blocked 
NF-κB activity in pancreatic cancer cells and made chemotherapy drugs gemcitabine, 
oxaliplatin, or irinotecan more potent.  Inhibition of TAK1 using either shRNA or TAK1 
kinase dead mutant resulted in cell apoptosis, decreased pancreatic cancer cells invasion and 
significantly reduced the size of tumors in orthotopic mice model. These findings highlighted 
that TAK1 could be a potential therapeutic target candidate for pancreatic cancer. 
 
      To our knowledge, our present study is the first to demonstrate that silencing the 
expression of TAK1 leads to a proapoptotic phenotype in pancreatic cancer cells and in turn 
to their significantly higher sensitivity to the antitumor activity of chemotherapeutic drugs 
with different mechanisms of action. Considering the oxaliplatin in particular, whereas the 
IC50s for this drug in control pancreatic cancer cells were higher than those achievable in 
patients [137], we found that silencing TAK1 decreased the IC50s for oxaliplatin into the 
range of plasma concentrations achievable in patients.  
 
      To confirm the results we obtained through genetic silencing of TAK1 expression, and to 
validate TAK1 kinase therapeutic target for treatment of pancreatic cancer patients, we 
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investigated the antitumor activity of the TAK1 kinase selective inhibitor LYTAK1 as a 
single agent and in combination with gemcitabine, oxaliplatin, or irinotecan. In a different 
study, screening for compounds that can inhibit TAK1 kinase activity resulted in the isolation 
of one natural compound, 5Z-7-oxozeaenol, a resorcylic lactone of fungal origin with a 
selective TAK1-inhibiting activity [89]. Together with anti-inflammatory activity, 5Z-7-
oxozeaenol has recently demonstrated to potentiate in vitro the TRAIL- induced apoptosis in 
lung cancer cells [105]. To our knowledge, our current study is the first to demonstrate that 
targeting the kinase activity of TAK1 with the selective inhibitor LYTAK1 potentiate in vitro 
the antitumor activity of gemcitabine, oxaliplatin, or irinotecan against a panel of pancreatic 
cancer cells.  
 
      The potent in vitro antitumor activity of the pharmacological inhibition of TAK1 kinase 
activity in contrast to the milder proapoptotic phenotype demonstrated by the TAK1 
knockdown pancreatic cancer cell lines could be due to different reasons. LYTAK1 is a 
potent and selective kinase inhibitor resulting in the almost complete inhibition of TAK1 
activity, which in part may explain its cytotoxicity in vitro as single agent. On the other hand, 
shRNA did not completely silence the expression of TAK1, which may explain why TAK1 
knockdown cells survived. Furthermore, our unpublished data from somatic cell (HCT116) 
knockout experiments indicated that complete ablation of TAK1 is lethal, consistently with 




      In line with other murine models carrying a tissue- specific deletion of the TAK1 gene 
[92, 94, 138], during the preparation of this manuscript two studies reported that TAK1 
conditional ablation in liver parenchymal cells causes an early (6 weeks) spontaneous 
apoptosis of hepatocytes and cholangiocites [139, 140]. This leaded to chronic hepatitis, 
cholestasis, liver fibrosis, and to a subsequent compensatory liver cell proliferation that at 
later time point (16-33 weeks) drives carcinogenesis in the liver. The additional deletion of 
the receptor for TNF- was able to significantly suppress liver damage and inflammation 
[139]. Whereas the spontaneous apoptosis of TAK1 knockout liver parenchymal cells is 
consistent with our observations in pancreatic cancer cells, these works could raise concerns 
on the potential hepatic toxicity of the pharmacologic inhibition of TAK1. As indicated 
before, in our work all regimens were well tolerated, and no weight loss or other signs of 
acute or delayed toxicity were observed. The low levels of TNF- in athymic nude mice kept 
under germ-free condition could explain the safety of LYTAK1 in comparison to the 
spontaneous apoptosis and inflammation observed in mice not kept under axenic conditions 
[139, 140], and in particular the lack of activity in vivo of LYTAK1 as single agent 
treatment. In absence of other activator of apoptosis, the pharmacologic inhibition of TAK1 
induced apoptosis of pancreatic cancer cells only when combined with proapoptotic 
chemotherapeutic agents.  
 
      Given its complex role in pancreatic cancer biology, targeting the TGF-β signaling 
pathways represents a challenging but important opportunity for the development of novel 
treatment for pancreatic cancer patients [141, 142]. In a different study, we investigated 
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whether targeting the TGF-β signaling though inhibition of TGF-β receptors I/II kinase 
activity was a valid therapeutic approach to suppress growth and metastatic spread of 
pancreatic cancer [128]. Whereas we observed that targeting the kinase activity of the TGF-β 
receptor suppressed the Smad- dependent pathway and in turn significantly inhibited 
pancreatic cancer metastasis, we found that the combination of TGF-β receptor inhibition and 
gemcitabine resulted in a relatively minor impact on pancreatic tumor growth and mice 
survival. More recently, it has been demonstrated that the activation of TAK1 by TGF-β 
occurs in a TGF-β receptor kinase- independent manner [143]. These results suggest that 
targeting the kinase activity of TGF-β receptors I/II would not be likely to suppress the 
activation of TAK1, thereby explaining the weak potentiation of gemcitabine observed [128]. 
 
      In the past two decades, the research for pancreatic cancer therapy has been focused on 
several molecules that are early players in the signal transduction cascade, with particular 
interest in membrane receptors such as the Epidermal Growth Factor Receptor (EGFR) 
[144]. From the results of the clinical trials with inhibitors of this receptor in pancreatic [145]  
and colorectal cancer [146], we have learned that the single mutation of K-Ras, the most 
common genetic alteration in pancreatic cancer, is probably able to circumvent the antitumor 
activity of anti-EGFR approaches. On the other hand, strategies for the direct inhibition of 
the final players of the signal transduction cascade such the transcriptional factor NF-B still 
face enormous challenges [134]. As a member of the MAP3K family, TAK1 is unique [136]. 
More than a single enzyme, it may be considered rather as the active component of a larger 
protein signaling complex made up of a variety of proteins such as TAK1 binding proteins 
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(TABs) and TRAF6, explaining its role as a key regulator of several signal transduction 
cascades. We believe that targeting no redundant cytosolic mediators of the signal 
transduction cascade such as TAK1 could represent a better approach to inhibit key processes 
in tumor cells. 
 
1.4.2. TAK1 activity is regulated in pancreatic cancer cells by TAB1. 
 
      TAB1 was initially identified as a TAK1 binding protein and many studies have 
demonstrated that TAK1 activity I regulated by TAB1. However, NF-B is still activated in 
TAB1 null MEF cells by TNF-α and IL-1. Our studies demonstrated that TAK1 and TAB1 
are highly correlated in almost all of pancreatic cancer cells and they are stabilized by each 
other. Furthermore, silencing TAB1 suppressed NF-B activation. This result is conflicted 
with that from MEF cells.  One explanation is that TAB1 function may be cell type 
dependent.  In the context of TAK1 overexpression in Panc-1 cells, TAB1 may be involved 
in NF-B activation through stabilizing TAK1 protein level.  We tried to knock down TAB1 
level in several different pancreatic cancer cell lines, but we only obtain the effective 
knocking down result in Panc-1 cells (data not shown).  Thereby, we don’t know whether 




      Importantly, TAB1 knocking down significantly reduced tumor burden in the Orthotopic 
Xenograft models.  As far as we know, this the first time to demonstrate TAB1 plays a role in 
pancreatic cancer tumorigenicity. Disruption of the interaction of TAK and TAB1 may 
reduce TAK1 level and therefore regulate TAK1 activity. Our results provide a new insight 
that the interaction of TAK1 and TAB1 may be used as a therapeutic target for pancreatic 
cancer. 
 
      In conclusion, this study is the first to demonstrate that the genetic silencing or the 
inhibition of the kinase activity of TAK1 is a valid approach to revert the intrinsic 
chemoresistance of pancreatic cancer. LYTAK1 is the first TAK1 selective inhibitor to be 











CHAPTER 2.  THE REGULATORY MECHANISM OF TAK1 BY TAB1 




2.1.1. TAK1 interaction proteins 
 
      A lot of studies have indicated that TAK1 is regulated by its binding proteins including 
TAB1, TAB2, TAB3 and TAB4 and post-translational modification such as phosphorylation 





      TAB1 was originally identified as a TAK1 interaction protein with yeast –two- hybrid.  
TAB1 interacts with the N-terminus of TAK1 and the C-terminus of TAB1 is sufficient to 
activate TAK1 upon TGF-β stimulation in the overexpression experiments [124].   As 
introduced before,  Co-expression of MOM-4  and TAP-1, which are the homologs of TAK1 
and TAB1 in C.elegance respectively,  stimulate MOM-4 MAP3K activity [76].  
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Coexpression of mTAK1 with hTAB1 resulted in reduced eye size in drosophila 
in transgenic flies [81]. TAK1 and TAB1 mediate BMP signaling pathway in xenopus at the 
early stage of development.  TAB1 enhanced the function of TAK1 in inducing the formation 
of ventral mesoderm [85]. 
 
      Target deletion of TAB1 in mice results in embryonic lethality E15.5 and E18.5. The 
development of heart and lung is largely impaired in TAB1 deficient embryos.  TAB1 is 
required for TAK1 kinase activity which phosphorylates MKK6 in vitro and the reporter 
gene activity in response of TGF-β stimulation [147].  However, the role of TAB1 in the 
control of TAK1 activity is still controversy.  It was reported that IL-1 induced NF-κB 
activation was not affected but IL-1 or TNF-α induced TAK1 activity was severely inhibited 
in TAB1 deficient cells [135].  These contradictory reports demonstrated that more detailed 
analysis is required to dissect the function of TAB1 in regulating TAK1 activity. 
 
      It has been reported that the N-terminal domain of TAB1 is similar with protein 
phosphatase 2C (PP2C), however, the mutagenesis and structural analysis demonstrated that 
TAB1 does not have the catalytic activity [148]. TAB1 Biochemical and structural analysis 
indicated that the N-terminal domain of TAB1interacts with the BIR1 domain of X-linked 







      TAB1 was also isolated by yeast –two- hybrid.  In contrast to TAB1, the C-terminal 
domain of TAB2TAB2 interacted with the C-terminal domain of TAK1 [124, 125] .  
Biochemical experiments revealed that TAB1 acts as an adapt protein to mediate the 
interaction of TRAF6 and TAK1. The C-terminal domains of both TAK1 and TAB1 have the 
coiled-coil motif, which may provide the protein interaction between TAK1 and TAB1.  
Cotransfection of TAB2 into 293 cells is not sufficient to induce TAK1 kinase activity that 
phosphorylates MKK6. However, TAB2 mediate NF-κB activation and JNK activation in a 
dose dependent manner followed by IL-1 stimulation and the C-terminal region of TAB2 acts 
as a dominant-negative mutant to block NF-κB activation and JNK activation in response of 
IL-1 stimulation.  However, the C-terminal region of TAB2 is unable to block NF-κB 
activation induced by TNF-α [125]. 
 
      Targeted deletion of TAB2 in mice induced increased apoptosis of hepatoblasts and 
therefore resulted in embryonic lethality at day 12.5.  However, NF-κB activation induced by 
TNF-α and IL-1 is normal in TAB2 deficient cells. These data demonstrated that TAB2 nay 






      TAB3 was initially identified in xenopus using cDNA microarrays [151].  TAB3 was 
found from human and mice EST database according to the homolog of TAB2 and the full 
length TAB3 was isolated from a human kidney cDNA library. Expression of TAB3 in 293T 
cells enhanced NF-κB activation.  Cooverexpression of TAB3 increased the kinase activity 
of TAK1 and induced JNK activation.  Either TAB2 or TAB3 siRNA alone did not block 
NF-κB activation, however, combination of TAB2 with TAB3 significantly impaired block 
NF-κB activation. These results implicated that TAB2 and TAB3 may have a redundancy 
function [152].   
 
      It was reported that both TAB2 and TAB3 contain a Zn finger (ZnF) domain which can 
bind the polyubiquitination chains.  Once stimulated by IL-1 and TNF-α, the 
polyubiquitination chains of RIP or TRAF6 interact with the ZnF domain of TAB2 and 




      TAB4 was initially called type 2A-interacting protein (TIP), which firstly identified as 
the homolog of the yeast Tip41 protein from a human T-cell lymphoma cDNA library. 
Immunoprecipitation experiments demonstrated that TIP bound with PP2A family members 
consisting of PP2Ac, PP4c and PP6c. TIP was shown to inhibit PP2A activity in the 
ATM/ATR signaling pathway [154].  TAB4 transiently associated with TAK1 at 5 minute 
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and disassociated at 15 min after IL-1β stimulation.  Overexpression of TAB4 in 293T cells 
increased TAK1-TAB1 kinase activity and induced NF-κB activation [155].  
 
2.1.2. Overview of Posttranslational modification (PTM) 
 
      Posttranslational modification (PTM) is a later step after protein translation. The common 
modification includes phosphorylation, methylation, acetylation, ubiquitination and 
glycosylation. Protein modification plays a very important role in the control of the functions 
of a protein, for example, protein stability, protein interaction, protein-DNA interaction, 
activating or inactivating an enzyme. We will give a brief review for several common 
posttranslational modifications. 
 
     2.1.2.1. Phosphorylation: Phosphorylation is the most intensively studied 
posttranslational protein modification. A phosphate (PO43-) group was added to Serine, 
Threonine  or Tyrosine  during phosphorylation.  Phosphorylation is catalyzed by kinase and 
reversed by phosphatases. Phosphorylation introduces negative charges and therefore 
changes protein conformation from hydrophobic to hydrophilic properties, which regulates 
protein function in the multiple processes such as protein stability, protein interaction and 
enzyme activity. For example, in canonical NF-κB signaling pathway, is caused by IKK-
induced phosphorylation [156].  It was reported that the interaction of MDM2 with p53 was 
reduced by the phosphorylation at Thr-216 [157]. In MAP kinase pathway, the stress-
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activated protein kinases (SAPKs) activator (SEK1) is activated by MEKK1 induced 
phosphorylation [158].  
 
      2.1.2.2. Methylation: Protein methylation is the addition of a methyl 
group to arginine or lysine amino acid of a protein  [159].  According to the structures of the 
guanidino nitrogens of arginine and  the ε-amino group of lysine, arginine can be methylated 
at most twice and lysine can be methylated at most three times, respectively.  
 
      Dimethylation of arginine can be grouped into two different sub types: 1. asymmetric 
NG,NG-dimethylarginine (aDMA) catalyzed by type I peptidylarginine 
methyltransferases (PRMTs) in which two methyl groups are added on the same one nitrogen 
and 2, symmetric dimethylated arginine catalyzed by type II PRMTs in which two methyl 
groups are added on both nitrogens.  Several arginine methyltransferases including PRMT1 
through 9 have been identified in mammalian and the substrate specificity of some PRMT 








 Figure 26.  Biochemical mechanisms for protein-lysine and protein arginine 
methylation. Trends in Biochemical Sciences Volume 32, Issue 3, March 2007, Pages 




      Protein-lysine methylation is most studied in histone.  Multiple lysine sites in the H3 and 
H4 histone subunits have been identified [161, 162]. Lysine methylation is reversible and 
LSD1, which is a homolog of the amine oxidase homolog, has been identified as the first 
demethylase [163]. Protein methylation is involved in multiple processes such as protein 
stability, protein interaction, transcriptional regulation, enzyme activation and mRNA 
splicing (Paik, Paik et al. 2007). 
 
      2.1.2.3. Ubiquitination 
 
      Ubiquitin is a small peptide consisting of 76 amino acids, which is highly conserved from 
yeast to human.  Ubiquitination is one of the most well known posttanslational modifications 
in which one or  several ubquitin molecules are added to the lysine of the targeted protein. 
Ubiqutination was initially identified as the major mechanism of  protein degradation.  Three 
sequential steps are involved in protein ubiquitination and each step is catylazed by the 
corresponding enzyme [164]. 
 
      In the first step, the C-terminal glycine  of ubiquitin  forms a high energy thiol-ester bond 
with the a cysteine of  the ubiquitin-activating enzyme E1. This reaction is ATP dependent 
and  the activated ubiquitin is produced during this step. In the following step, the activated 
ubiquitin from the high energy thiol-ester bond is passed on to the substrate by the ubiquitin-
conjugating enzyme E2. In the final step,  the substrate bound ubiquitin protein ligase E3 
catalyzes the formation of a isopeptide bond between the ε-NH2 group of a lysine on the 
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substrate and the C-terminal glycine on a ubiquitin. The cycle consisting of the above three 
steps can be repeated to produce ubiquitin chains. The protein tagged with ubiquitin is 
targeted to the 26S proteosome for degradation. The ubiquitin molecules are removed from 
the proteins before degaration and the free ubiquitin molecules can be recycled.  In most 
cases, the substrate sepecificity of ubiquitination is largely determined by E3 ligase and also 
depends in part on E2 enzyme. A lot of E2 and E3 enzymes have been identified [164] .  
 
      Ubiquitin contains seven lysine residues (Lys6, Lys11, Lys27, Lys29, 
Lys33, Lys48 and Lys63) .  A proteomics study using mass spectrometry  demonstrated that 
polyubiquitin chain can be attached at any of these seven lysine sites  [165]. The lysine 48 
and lysine 63 are the most well known  conjugating and the fuction of ubiquitination at other 
lysine site is still largely unknown.  Historically the original studies were focused on the 
lysine 48 chains which is responsible for protein degradation.  However, most recent studies 
have extended the role of ubiqutination from protein degradation to a variety of signaling 
pathways. The most well known sample is the role of  lysine 63-linked ubiqutination in NF-
κB signaling pathway.  It was reported that TAK1 interacted with the lysine 63-linked 
ubiquitination chain of TRAF6 through TAB2 or TAB3 upon IL- stimulation and 
furthermore activate the downsream IKK-IκBα - NF-κB cascade [136]. 
 
      The recent studies have identified a new Ubiquitination during which a head-to-tail (Ub1 
Gly76 to Ub2 Met1) linkage of polyubiquitination chain is produced.  This 
polyubiquitination chain is conjugated to Lys 285 and Lys 309 in the coiled-coil 2 (CC2) and 
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leucine zipper (LZ) domain of NF-κB essential modulator (NEMO, or called IKKγ). 
Linear ubiquitin chain assembly complex (LUBAC), which contains two RING finger 
components HOIL-1L and HOIP, induces the formation of the linear polyubiquitin chain and 
is required for the canonical NF-κB activation [166, 167]. 
 
      Like phosphorylation, methylation, ubiquitination is also a reversible process.  The 
cleavage of ubiquitin from substrates is catalyzed by deubiquitinating enzymes (DUBs). As 
the reverse of Ubiquitination, deubiquitination plays an important role in multiple processes 
such as kinase activation, protein interaction, protein degradation, endocytosis and regulation 
of chromatin structure and transcription [136, 168-170]. Increasing evidence demonstrates 
that deubiquitinating enzymes have high substrate specificity such as ubiquitin chain 
specificity (Lys48 and Lys 63), the selection of  ubiquitin and ubiquitin-like molecules 
(NEDD8, ISG15, Sumo and Atg8  etal.), and DUB/E3 and interactions [170].  Approximate 
95 genes encoding putative human deubiquitinating enzymes have been identified by 
bioinformatics according to the DUBs catalytic domains  composed of five 
subgroups:  ubiquitin-specific protease (USP), ubiquitin C-terminal hydrolase (UCH), 
Otubain protease (OTU), and Machado-Joseph disease protease (MJD) and 
JAB1/MPN/Mov34 metalloenzyme (JAMM) [170].  
 




      Acetylation is a very important post-translational modification in both prokaryotes  and 
eukaryotes.  Protein acetylation is grouped into two major classes: acetylation of N-terminal 
alpha-amine and acetylation of lysine.  
 
     N-terminal acetylation of proteins is one of the most well known protein post-translatioal 
modification with the addition of acetyl group onto N-terminal alpha-amine. More than 80% 
of proteins in eukaryotes are acetylated. This modification is irreversible and it is a very early 
and cotranslational event occuring when only about 25–50 amino acid residues of the nascent 
polypetide are extruding from the ribosome [171]. Little is known about the function of the 
acetylation of N-terminal alpha-amine. It was reported that  the translocation of  into 
endoplasmic reticulum was blocked by N-terminal acetylation [172].  Drosophila actin I is 
firstly translated as a precursor and followed by N-terminal acetylation, which plays a role in 
assembling microfilaments in vitro [173].  The role of N-terminal acetylation in stabilizing 
protein is controversial.  The current view is N-terminal acetylation protects proteins from 
ubiquitination and  therefore stablizes proteins. This view is supported by the experiments 
from several proteins such as cytochrome c, enolase, p16 and p14/p19ARF [174-177]. In 
contrast to with the prevalent view, the most current study provides  the evidence that N-
terminal acetylation of Met acts as the N-terminal degradation signals ( called N-degrons) 
and N terminal-acetylated Ala, Val, Ser, Thr, and Cys residues are also recognized by  the E3 
ligase Doa10  of  yeast. These two contradictory effects of N-terminal acetylation on protein 
stability may be determined by the folding of the N-terminal domain of the nascent proteins.   
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The rapid folding protects the protein from degradation while the delayed or defective 
folding results in degradation [178]. 
 
      Most studies of acetylation are focused on acetylation of lysine. The acetyl group was 
attached onto the ε-amino group of lysine during acetylation. The side chain of lysine 
containing the ε-amino group has a pKA value of approximate 10.53, therefore carrying 
positive charge at the pH of 7.  Acetylation of lysine resulted in the removal of 
positive charge of the side chain and therefore generates two effects:  (1) Reduce the affinity 
of the histone tail for negative charged DNA and produce a loose and relaxing of highly 
packed and order chromatin structure. Consequently, the transcriptional factors are able to 
bind DNA to activate transcription [179]; (2) Provide a docking site for the recruitment of 
transcriptional coactivators which contain bromodomains [180]. 
 
      Histone acetylation is one of the most commonly studied modifications.  The 
accumulating number of lysine sites has been identified as acetylation in histone H2A, 
H2A.X, H2B, H3 and H4 (http://www.millipore.com/techpublications/tech1/pb1014en00). 
Most of these sites are located in the N-terminus. As discussed above, acetylation resulted in 
the removal of positive charge. Neutralization of positive charge may change the interactions 
between histone and DNA or proteins. The alterations in these interactions could provide a 
more open and accessible conformation of chromatin for transcriptional factors and therefore 
modulate gene expression [181-183].   
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      Lysine acetylation is catalyzed by histone acetyltransferases (HATs). A lot of histone 
acetyltransferases which catalyze the transferring of the acetyl group onto the ε-amino group 
of lysine specific residues of histone have been identified by the different labs. Histone 
acetyltransferases are grouped into five families composed of p300/CBP HATs, GCN5-
related N-terminal acetyltransferases (GNATs), MYST family (including MOZ, Ybf2/Sas3, 
Sas2, and Tip60), the general transcription factor HATs (including the TAFII-250 family) 
and the nuclear hormone- related HATs ( including SRC1 and ACTR) [184]. 
 
      P300/CBP is required for embryonic development in C.elegans, drosophila, mouse and 
human. RNAi experiments demonstrated that CBP-1, the C.elegans homolog of mammalian, 
is required for endoderm and mesoderm development [185]. Genetic screen and 
identification demonstrated that a deletion of CBP-1 results in embryonic lethality in c. 
elegans [186]. Drosophila CBP is involved in embryonic development such as establishment 
of dorsal-ventral polarity through the regulation of the transcriptional factors such as Cubitus 
interruptus twist and snail in Hedgehog, Wingless-Engrailed, TGF-β homolog 
Decapentaplegic (Dpp) signaling pathway [187-189]. CBP and p300 are indispensable early 
embryonic development in mice. Loss of only one copy of either p300 or CBP gene is 
sufficient to result in embryonic lethality. These results indicate that the requirement of 
normal embryonic development for CBP and p300 is dose dependent [190].  In human, CBP 
is associated with Rubinstein-Taybi syndrome.  Multiple mutations of CBP and p300 have 
been identified by DNA sequencing in patients with abnormal features including long eye    
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lashes, heavy and arched eyebrows, a prominent nose with a long hanging columella, a 
pouting lower lip, square distal fingertips, a shortened and broad thumb [191, 192]. 
 
      Members of the GNAT family are shown to play an essential role in DNA repair, cell 
cycle progression, and embryonic development.  Loss of GCN5 leads to a cell cycle blockage 
at the G2/M phase in yeast [193] . Target deletion of GCN512 in mice causes elevated 
apoptosis, development defect and embryonic lethality [194].  
 
      It was shown that p53 is regulated by Tip60 at two distinct levels: (1). Firstly it acts as 
the coactivator of p53 to induce transcription of the downstream target genes such as p21; (2) 
second, it is able to block E3 ligase Mdm2-induced ubiquitination and therefore protect p53 
from degradation. Therefore it implicates that Tip60 is associate with DNA damage repair 
[195]. The expression level of Tip60 is changed in human cancer.  Tip60 expression is 
downregulated in colon and lung carcinomas [196]. However, upregulation of Tip60 protein 
is associated with the onset of prostate cancer through the acetylation of the androgen 
receptor (AR) [197]. These contradictory reports demonstrate that Tip60 play diverse roles in 
cancer progression and may not directly function as an oncogene or tumor suppressor gene 
[198]. The other members of MYST family such as HBO1 (MYST2), MOZ and MORF are 




      TAFII-250 is one subunit of the transcription initiation factor TFIID.  Drosophila TAFII-
230 is the homolog of human TAFII-250.  Drosophila TAFII-230 has been identified to have 
intrinsic HAT activity. Like hGCN5 and P/CAF, dTAFII230 displays the specific HAT 
activity for H3 and H4. TAFII-250 induced acetylation of nucleosomes could result in 
changes in conformation and therefore increase promoter exposure to transcription factors 
[200].  
 
      Both steroid receptor coactivator-1 (SRC-1) and a novel cofactor (ACTR), which interact 
with nuclear hormone receptors, have been shown to have HAT activity. H3 and H4 can be 
acetylated by recombinant SRC-1. ACTR increases the reporter gene activity induced by the 
nuclear hormone receptor retinoids (RARs) [201, 202]. 
 
      The function domains of different HATs have been identified. The catalytic mechanisms 
of several HATs such as GCN5 and PCAF have been studied in detail by biochemical 
approaches [183, 203-205]. The high resolution crystal structure  and site mutagenisis 
analysis of GCN5 have revealed the mechanism by which a conserved glutamate 
residue(E173) plays an essential role in the substrate binding and catalysis [206]. However, 
the selective HAT inhibitor of PCAF, composed of peptide/CoA conjugate, does not have 
effect on the activity of p300. This implicates that the family of p300/CBP and the family of 




      A lot of studies have identified the HATs substrate specificities for histone. However, 
there is accumulating  evidence that HATs also acetylate a variety of non-histone proteins 
[208]. Several samples will be given as below.  
 
      (1). P53 is the most well known protein of non-histone substrates.  It has been convincely 
shown that he DNA binding activity of p53 is largely regulated by p300/CBP mediated 
acetylation at several lysine residues of c-terminus [209, 210].  
 
       (2). Rel A subunit of NF-κB m is acetylates by p300/CBP at 218, 221 and 310. 
Acetylation of 218 weakens the interaction with IκBα and inceases DNA binding activity. 
Acetylation of 310 increases transcription activity [211, 212].  
 
      (3).The transcriptional factor smad7 is acetylated by p300 at 64 and 70. Acetylation 
protects smad7 from degradation by the ubiquitin E3 ligase and therefore enhances protein 
stability [213].  
 
      (4). The lysines 873 and 874 at the C terminus of the retinoblastoma (Rb) tumor 
suppressor is acetylated by p300 and PCAF.  Acetylationof Rb is negatively corelated with 
the phosphorylation by E-Cdk2 and subsequently inhibits cell cycle progression. Rb 
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acetylation also enhances binding affinity with MDM2 [214, 215]. The lysines 117, 120 and 
125 in  the N-terminal DNA binding domain of  E2F1 are acetylated by PCAF.  Acetylation 
of E2F2 increases DNA binding activity, protein atability and the interaction with p73 and 
therefore contributes apoptosis [216-218].   
 
      (5). The transcription fator stat3 is acetylated at lysine 685 by p300/CBP. Acetylation 
increases stat3 dimerization and thereby enhances DNA binding affinity and transactivation 
[219, 220].  
 
      (6) Nuclear receptors such as androgen receptor (AR) and estrogen receptor are 
acetylated by p300. Acetylation at the lysines 630, 632 and 633 is necessary for DNA 
binding activity of AR [221, 222].  The lysines 299, 302 and 303 of the estrogen receptor α 
(ERα) are acetylated by p300 [223]. It seems that acetylation of (ERα) produces opposite 
effects on trancription based on the context:  weakens hormone induced transcription but 
enhancse the basal transcription [224].  
 
      (7). Yin Yang 1 (YY1) is a tarnscription factor which is involved in both transcription 
activation and repression [225]. Transcriptional activity  is regulated by the acetylation and 




      (8).  α-Tubulin is well knoawn as a cytoskeletal protein.  Tubulin acetylation could be 
involved in cell motility. Microtubules are classified into two subtypes:  stable microtubules 
with a half-life of hours and dynamic microtubules with a half-life of only 5–10 min. α-
tubulin is acetytlated atmuch higher level in table microtubules than in dynamic 
microtubules. Deactylation of α-tubulin at lysine 40 is catalyzed by the histone 
deacetylases, HDAC6 and SIRT2 [227-229]. Over-expression of HDAC6 reverses 
acetylation of  α-tubulin, results in depolymerization of microtubule and therefore 
enhance  cell motility [227]. 
 
      Like other post-translational modifications, acetylation is also reversible. So far 18 
histone deacetylases (HDAC) have been identified in human human and they are clsssified 
into four groups according to their homology to yeast HDACs [230, 231].  The class I 
HDACs are composed of four members (HDACs 1, 2, 3, and 8) , which are homologs of  to 
the yeast RPD3  protein. They are detected  in nucleus fraction; the class II HDACs includes 
six members (HDACs 4, 5, 6, 7, 9, and 10) , which are homologs of  to the yeast HDA1  
protein. They are located in both the nucleus and cytoplasm fractions; the class III HDACs 
are composed of seven sirtuin proteins (SIRT1, 2, 3, 4, 5, 6 and 7), which are homologs of 
the yeast protein sirtuin2 (Sir2). All of these seven sirtuin proteins share an evolutionary 
conserved core domain composed of a NAD+ domain and a catalytic domain. The SIRT 
family requires NAD+ for their activity; the class IV HDACs includes only one member 
(HADC11).  HDAC11 shares conserved residues with both class I and II HDAC enzymes 
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and therefore considered as a atypical group[232]. HDAC11 is found in both nucleus and 
cytoplasm fractions.  
 
      HDACs have been shown to be involved in a variety of signaling pathways.  HDACs are 
opposite to HATs and therefore regulate gene expression by the removal of acetyl groups.  It 
has been demonstrated that HDACs are associated with some diseases such as cancer. In 
acute myeloid leukaemia (AML), the recruitment of the N-CoR histone deacetylase complex 
to the fusion oncoproteins PML–RARA and PLZF–RARA leads to a repression of retinoic 
acid induced target genes [233].  The NAD+-dependent deacetylase SIRT1 has been shown to 
negatively regulate Notch signaling in endothelial cells. Deacetylation counteracts the 
stability of the Notch1 intracellular domain (NICD) by acetylation. Inhibition of SIRT1 
activity by siRNA or nicotinamide (NAM) promotes the stability of NICD and thereby 
increases the activity of Notch target genes such as Nrarp, Hey2 and Lfng upon Notch ligand 
DLL4 stimulation [234]. The treatment for acute myeloid leukemia cell line MLL-AF9  with 
the HDAC inhibitor (HDACi) valproic acid (VPA) induces G1 cell-cycle arrest and apoptosis 
in a p21 dependent manner [235].  
 
      Many deacetylase inhibitors have been discovered and the most well known samples 
are nicotinamide (NAM)  and trichostatin A (TSA). The sirtuin Class III HDACs including 
SIRT1, 2, 3, 4, 5, 6 and 7 contain a conserved NAD+ domain and thereby are inhibited by the 
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binding of nicotinamide [236]. The Class I and II HDACs including HADC1 to HADC10  
are inhibited by trichostatin A. 
 
2.2. Materials and methods 
 
2.2.1. Primers and constructs: 
 
2.2.1.1. TAB1 primers and constructs: 
 
5’ primer: (BamHI):  CCC GGATCC GCC GCC ACCATGGCGGCGC AGAGGAGGAG C 
3’ primer :( EcoRI+ HA tag): CCC GAA TTC TCA AGC GTA GTC CGG AAC GTC GTA 
CGG GTA  CGG TGCTGT CAC CAC GCT CTG C 
3’ primer for N-terminal 418 AA: (EcoRI + HA tag): CCC GAA TTC TCA AGC GTA GTC 
CGG AAC GTC GTA CGG GTA  GAC CAT CTG GCC CTG GGA GGG 
5’ primer for C-terminal 68 AA: (BamHI): CCC GGA TCC GCC GCC ACC ATGCA 
AAGCCCGACC TTAACCCTGC 
5’ primer for C-terminal 58 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG AA 
CACGCACACG CAGAGCAGCA GC 
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5’ primer for C-terminal 48 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG  TC 
TGACGGAGGC CTCTTCCGCT CC 
5’ primer for C-terminal 38 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG  GC 
CCACTCGCTC CCGCCTGGCG 
5’ primer for C-terminal 28 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG  CG 
TGTTGAGCCC TATGTGGACT 
5’ primer for C-terminal 18 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG  TT 
TTACCGCCTC TGGAGCGTGG 
5’ primer for C-terminal 8 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG  GA 
GCAGAGCGTG GTGACAGCAC 
5’ primer for C-terminal 25 AA: (BamHI): CCC GGA TCC GCC GCC ACC   ATG CCC 
TATGTGGACT TTGCTGAG 
3’ primer (1479-1462) (EcoRI -HA-tab1 1479-1462) (named 3’ c-11, last 11 aa deleted):  
CCC GAA TTC CTA  AGC GTA GTC CGG AAC GTC GTA CGG GTA    CAC GCT 
CCA GAG GCG GTA  
3’ primer (1476-1459) (EcoRI -HA-tab1 1476-1459) (named 3’ c-12, last 12 aa deleted): 
CCC GAA TTC CTA  AGC GTA GTC CGG AAC GTC GTA CGG GTA    GCT CCA 
GAG GCG GTA AAA  
3’ primer (1473-1456) ( EcoRI -HA-tab1 1473-1456) (named 3’ c-13, last 13 aa deleted): 
CCC GAA TTC CTA  AGC GTA GTC CGG AAC GTC GTA CGG GTA    CCA GAG 
GCG GTA AAA CTC 3’ primer (1470-1453) (EcoRI -HA-tab1 1470-1453) (named 3’ c-14, 
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last 14 aa deleted): CCC GAA TTC CTA  AGC GTA GTC CGG AAC GTC GTA CGG 



















 Construct Cloning sites vector 
1 Full length BamHI+EcoRI pcDNA3.1 
2 Full length with HA BamHI+EcoRI pcDNA3.1 
3 N418        with HA BamHI+EcoRI pcDNA3.1 
4 C68          with HA BamHI+EcoRI pcDNA3.1 
5 C58          with HA BamHI+EcoRI pcDNA3.1 
6 C48          with HA BamHI+EcoRI pcDNA3.1 
7 C38          with HA BamHI+EcoRI pcDNA3.1 
8 C28          with HA BamHI+EcoRI pcDNA3.1 
9 C18          with HA BamHI+EcoRI pcDNA3.1 
10 C08          with HA BamHI+EcoRI pcDNA3.1 
11 C24          with HA BamHI+EcoRI pcDNA3.1 
12 C22          with HA BamHI+EcoRI pcDNA3.1 
13 C20          with HA BamHI+EcoRI pcDNA3.1 
14 C25          with HA BamHI+EcoRI pcDNA3.1 
15 C15-68     with HA BamHI+EcoRI pcDNA3.1 
16 C10-68     with HA BamHI+EcoRI pcDNA3.1 
17 C05-68     with HA BamHI+EcoRI pcDNA3.1 
18 C10-26     with HA BamHI+EcoRI pcDNA3.1 
19 C11-26     with HA BamHI+EcoRI pcDNA3.1 
20 C12-26     with HA BamHI+EcoRI pcDNA3.1 
21 C13-26     with HA BamHI+EcoRI pcDNA3.1 
 




2.2.1.2. TAK1ΔN22 primer: CCC GGA TCC GCC GCC ACC ATG TCGC 
AGGTCCTGAA CTTCGAAGAG 
 
 2.2.1.3. TAK1-TAB1 fusion primers: 
 
5’ flag-Human tak1 primer: ( BamHI + Kazak +Flag+ Linker +TAK 5’)(F1): CCC GGA 
TCC GCC GCC ACC  ATG GAT TAC AAG GAT GAC GAC GAT AAG GCC CGG GCG 
TCT ACA GCC TCT GCC GCC 
3’-Human TAK1 (EcoRI+TAK1 3’) (F5): CCC GAA TTC TGA AGT GCC TTG TCG TTT 
CTG 
5’ Linker TAB1 C-68 5’ (F7): CCC GAA TTC GGA GGA GGA GGA GGA CAA AGC 
CCG ACC TTA ACC CTG  
3’ Human TAB1 –HA (XhoI) (F4): CCC CTC GAG TCA  AGC GTA GTC CGG AAC GTC 
GTA CGG GTA  CGG TGCTGT CAC CAC GCT CTG C     
 Construct Cloning sites vector 
1 
Flag Full length TAK1 with TAB1 C68 
HA 
BamHI+XhoI pcDNA3.1 
2 Flag N303 TAK1 with TAB1 C68 HA BamHI+XhoI pcDNA3.1 
 




2.2.1.4. TAK1 site mutagenesis primers:  
 
S389A for: ACCTCTG AGGGCAAGAG GATG GCC GCT GACATGTCTG 
AAATAGAAGC TA 
S389A rev: TA GCTTCTATTT CAGACATGTC AGC GGC CATC CTCTTGCCCT 
CAGAGGT 
T440A for: CCCA GTGTCAGAAT GATTACT  GCC TCAGGACCAA CCTCAGAAAA 
GCC  
T440A rev: GGC TTTTCTGAGG TTGGTCC TGA GGC AGTAATC ATTCTGACAC 
TGGG 
S441A for: CCCA GTGTCAGAAT GATTACT  ACC GCC GGACCAA CCTCAGAAAA 
GCC 
S441A rev: GGC TTTTCTGAGG TTGGTCC GGC GGT AGTAATC ATTCTGACAC 
TGGG 
T440A, S441A for: CCCA GTGTCAGAAT GATTACT  GCC  GCC   GGACCAA 
CCTCAGAAAA GCC 
T440A, S441A rev: GGC TTTTCTGAGG TTGGTCC GGC GGC AGTAATC 
ATTCTGACAC TGGG 




K72R rev: CTGCCGAAGC TCTACAATAA ACGC TCT CCT CTCAGATTCA 
CTTTCTATTT 
K72Q for: AAATAGAAAG TGAATCTGAG AGG CAA GCGT TTATTGTAGA 
GCTTCGGCAG 
K72Q rev: CTGCCGAAGC TCTACAATAA ACGC TTG CCT CTCAGATTCA 
CTTTCTATTT 
K158R for: GCGCTAATTC ACAGGGACCT G AGA CCACCA AACTTACTGC 
TGGTTGCAGG 
K158R rev: CCTGCAACCA GCAGTAAGTT TGGTGG TCT C AGGTCCCTGT 
GAATTAGCGC 
K158Q for: GCGCTAATTC ACAGGGACCT G CAA CCACCA AACTTACTGC 
TGGTTGCAGG 
K158Q rev: CCTGCAACCA GCAGTAAGTT TGGTGG TTG C AGGTCCCTGT 
GAATTAGCGC 
K227R    for: GAAGTGATAA CGCGTCGG AGA CCCTTTGAT GAGATTGGTG 
K227R    rev: CACCAATCTC ATCAAAGGG TCT CCGACGCG TTATCACTTC 
K227Q    for: GAAGTGATAA CGCGTCGG CAA CCCTTTGAT GAGATTGGTG 
K227Q    rev: CACCAATCTC ATCAAAGGG TTG CCGACGCG TTATCACTTC 
K520R    for: CATTGTTATT ACAGAGA AGA CAAGAACTAG TTGCAGAACT 
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K520R    rev: AGTTCTGCAA CTAGTTCTTG TCT TCTCTGT AATAACAATG 
K520Q    for: CATTGTTATT ACAGAGA CAA CAAGAACTAG TTGCAGAACT 
K520Q    rev: AGTTCTGCAA CTAGTTCTTG TTG TCTCTGT AATAACAATG 
K562R    for: TTTCTACTTA CTACCAGCAA TGC AGA AAA C AACTAGAGG 
T CATCAGAAGT 
K562R    rev: ACTTCTGATG ACCTCTAGTT G TTT TCT GCA TTGCTGGTA 
G TAAGTAGAAA 
K562Q for: TTTCTACTTA CTACCAGCAA TGC CAA AAA C AACTAGAGGT 
CATCAGAAGT 
K562Q rev: ACTTCTGATG ACCTCTAGTT G TTT TTG GCA TTGCTGGTAG 
TAAGTAGAAA 
K563R for:  TTTCTACTTA CTACCAGCAA TGC AAA AGA C AACTAGAGGT 
CATCAGAAGT 
K563R rev: ACTTCTGATG ACCTCTAGTT G TCT TTT GCA TTGCTGGTAG 
TAAGTAGAAA 
K563Q for: TTTCTACTTA CTACCAGCAA TGC AAA CAA C AACTAGAGGT 
CATCAGAAGT 




K158N for: GCGCTAATTC ACAGGGACCT G AAC CCACCA AACTTACTGC 
TGGTTGCAGG 


















 Construct vector 
1 S389A pCMV-tag2A 
2 T440A pCMV-tag2A 
3 S441A pCMV-tag2A 
4 T440A, S441A pCMV-tag2A 
5 K72R pcDNA3.1 
6 K72Q pcDNA3.1 
7 K158R pcDNA3.1 
8 K158Q pcDNA3.1 
9 K227R pcDNA3.1 
10 K227Q pcDNA3.1 
11 K520R pcDNA3.1 
12 K520Q pcDNA3.1 
13 K562R pcDNA3.1 
14 K562Q pcDNA3.1 
15 K563R pcDNA3.1 
16 K563Q pcDNA3.1 
17 K158N pcDNA3.1 
18  K72R,  K227R pcDNA3.1 
19 K563R, K72R pcDNA3.1 
20  K563R. K227R pcDNA3.1 
21  K563R. K520R pcDNA3.1 
22  K72Q,  K227Q pcDNA3.1 
23 K563R, K72R, K227R (“3R”) pcDNA3.1 
24 K563R, K72R, K227R, K520R (“4R”) pcDNA3.1
 






2.2.1.5. TAK1 primers for bacteria expression constructs 
 
TAK1 5’ (BamHI): CCC GGA TCC TCGACAG CCTCCGCCGC CTCC 
TAK1 5' (EcoRI):   CCC GAA TTC TCGACAG CCTCCGCCGC CTCC 
TAK1 3' (XhoI):   CCC CTC GAG TGAAGTG CCTTGTCGTT TCTG 
K158amber for: GCGCTAATTC ACAGGGACCT G TAG CCACCA AACTTACTGC 
TGGTTGCAGG 
K158amber rev: CCTGCAACCA GCAGTAAGTT TGGTGG CTA C AGGTCCCTGT 
GAATTAGCGC 
 
2.2.1.6. TAB1 primers for bacteria expression constructs: 
 
TAB1  N Pet28A: CCC GAA TTC GCGGCGC AGAGGAGGAG CTTGC 
 TAB1 C  Pet28A: CCC CTC GAG CGGTGCTGTCACCACGCTCTGC 
 
2.2.1.7. MKK6 primers for bacteria expression constructs 
 
MKK6 was cloned from human 293T cell cDNA. 
125 
 
MKK6 N PGEX 4T1 (and 6P1): CCC GCGGCCGC AT 
TCTCAGTCGAAAGGCAAGAAGCG 
MKK6 C PGEX 4T1 (and 6P1): CCC   GCGGCCGC TC    
GTCTCCAAGAATCAGTTTTAC 
MKK6 K82A For: CC AGC GGG CA G ATC ATG GCA GTG GCG CGG A TC CGA 
GCC AC A GTA AAT AGC 
MKK6 K82A Rev: GCT ATT TAC TGT GGC TCG GAT CCG CGC CAC TGC CAT GAT 
CTG CCC GCT GG 
MKK6 S207A For: GGA ATC AGT GGC TAC T TG GTG GAC GCG GTT GCT AAA 
ACA ATT GAT G CA GG 
MKK6 S207A Rev: CC TGC ATC AAT TGT TTT AGC AAC CGC GTC CAC CAA GTA 
GCC ACT GAT TCC 
MKK6 T211A For: TAC T TG GTG GAC TC T GTT GCT AAA GCG ATT GAT G CA 
GGT TGC AA A CCA TA 
MKK6 T211A Rev: TA TGG TTT GCA ACC TGC ATC AAT CGC TTT AGC AAC AGA 
GTC CAC CAA GTA 
MKK6 S207A, T211A For: TAC T TG GTG GAC GCG GTT GCT AAA GCG ATT GAT 
G CA GGT TGC AA A CCA TA 
MKK6 S207A, T211A Rev: TA TGG TTT GCA ACC TGC ATC AAT CGC TTT AGC 
AAC CGC GTC CAC CAA GTA 
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  Construct vector 
1 
TAK1 
WT  PET 28A 
2 WT  PGEX 4T1 
3 WT  PGEX 6P1 
4 K63A  PGEX 6P1 
5 K158R  PGEX 6P1 
6 K158Q  PGEX 6P1 
7 K158N  PGEX 6P1 
8 K158 amber  PGEX 6P1 
9 K563R, K72R, K227R (“3R”)  PGEX 6P1 
10 K563R, K72R, K227R, K520R (“4R”) PGEX 6P1 
11 
TAK1TAB1C68 fusion 
WT  PGEX 6P1 
12 K63A  PGEX 6P1 
13 K158R  PGEX 6P1 
14 K158Q  PGEX 6P1 
15 K158N  PGEX 6P1 
16 K158 amber  PGEX 6P1 
17 K563R, K72R, K227R (“3R”)  PGEX 6P1 
18 K563R, K72R, K227R, K520R (“4R”) PGEX 6P1 
19 
MKK6 
WT PGEX 6P1 
20 K82A PGEX 6P1 
21 S207A PGEX 6P1 
22 T211A PGEX 6P1 
23 S207A, T211A PGEX 6P1 
24 
TAB1 
WT PET 28A 
25 WT PGEX 4T1 
26 WT PGEX 6P1 
 





2.2.1.8. MEKK3 primers: 
 
K522R  For: ACATGATTGTTCACCGGGACATTAGGGGAGCCAACATCCT 
 CCGAGACTCT 
K522R  Rev: AGAGTCTCGG AGGATGTTGG CTCC CCT AAT GTCCCGGTGA  
ACAATCATGT 
K522Q  For: ACATGATTGTTCACCGGGACATTCAGGGAG CCAACATCC 
T CCGAGACTCT 
K522Q  Rev: AGAGTCTCGG AGGATGTTGG CTCC CTG AAT GTCCCG 
GTGA ACAATCATGT 
K522N  For: ACATGATTGT TCACCGGGAC ATT AAC GGAG  
CCAACATCCT CCGAGACTCT 








 Construct vector 
1 WT pcDNA3.1 
2 Kinase dead pcDNA3.1 
3 K522R pcDNA3.1 
4 K522Q pcDNA3.1 
5 K522N pcDNA3.1 
 
Table5. MEKK3 constructs. 
 
 All constructs above were confirmed by DNA sequencing. 
 
2.2.2. Mass spectrometry  
 
Mass spec was performed at the Proteomics Core of Baylor College of Medicine. 
 
2.2.3. Reagents and cell lines: 
 
      Phospho-TAK1 (Thr184/187) Antibody, Phospho-MKK3 (Ser189)/MKK6 (Ser207) 
Antibody, Phospho-p38 MAPK (Thr180/Tyr182) (12F8) Rabbit mAb were purchased from 
cell signaling (#4531, #9231, #4631). Mouse Anti-MEKK3 Monoclonal antibody was 
purchased from BD Biosciences (#611102).  Human wildtype MEKK3, kinase dead MEKK3 
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and Phospho-MEKK3 are the generous gifts from Dr. Jianghua Yang (Baylor college of 
Medicine, Houston, Texas). CBP and p300 plasmids are the generous gifts from Dr. Mien-
Chie Hung (The University of Texas M. D. Anderson Cancer Center, Houston, Texas). 
GCN5 and PCAF plasmids are the generous gifts from Dr. Sharon Dent (The University of 
Texas M. D. Anderson Cancer Center, Houston, Texas). Tip 60 plasmid is the generous gift 
from Dr. Junjie Chen (The University of Texas M. D. Anderson Cancer Center, Houston, 
Texas). HA-ubiquitin plasmid is the generous gift from Dr. Shao-cong Sun (The University 
of Texas M. D. Anderson Cancer Center, Houston, Texas).  
 
 
      TAK1 rescue cell lines (vector control, WT, K158R, K158Q, and K158N) were 
established by Dr. Ruiying Zhao. The plasmids were transfected into TAK1 null MEF cells 
and selected by zeocine.  
 
2.2.4.. Cycloheximide (CHX) chase assay 
 
      TAK1 and TAB1 plasmids were transfected into 293T cells. AT 48 hours after 
transfection, cells were treated with 100 μg/mL CHX (Sigma) to inhibit protein synthesis and 




2.2.5. GST protein purification: 
1) Pick a single colon from a fresh agar plate and grow overnight at 37˚C in 4 ml LB with the 
selection in a 10ml tube on a shaker. 
2) Dilute 1:100 in 400ml LB with the selection and grow 3-4 hours at 37˚C in 1L bottle on a 
shaker until OD 0.6-0.8 is reached. 
3) Induce with IPTG (1mM final) for 4 hours at 30˚C. Spin the culture, remove the 
supernatant and collect pellets. Wash the pellets twice with cold PBS. 
4)  Resuspend the bacterial pellet in 15 ml lysis buffer (50 mM Tris-Cl, PH7.6, 150 mM 
NaCl, 10% glycerol, 0.5 mM EDTA, 250 µg/ml lysozyme and protease inhibitors) briefly 
sonicate the cells on ice for 6 x 10 second bursts (with 10 second intervals between each 
burst) using a Misonix XL 2020 sonicator fitted with a microtip probe and set at power 
setting 5.  
5) Spin down the lysed cells by high speed centrifugation at 12k, 30min at 4C and collect the 
soluble protein extracts (avoid the precipitations)  
6) While spinning, wash the 400 µl GSH beads (GE Healthcare, 17-0756-01) twice with lysis 
buffer.  
7) Transfer the GSH beads into the supernatant lysate and rotate at 4˚C for 3 hr. Spin down 
the beads at 4000g X 5 min. Wash three times with lysis buffer. 
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8) Add 400 glutathione buffer (10 mM Glutathione in 50 mM Tris pH 8.0, 10% glycerol ) 
elute for 1 hour at room temperature.  Repeat elution once and combine the eluates. Aliquot 
the eluates into eppendorf tubes and store them at -80˚C 
 
2.2.6. His-tag protein purification: 
 
      Ni-NTA affinity resin was purchase from QIAGEN. Binding and Wash buffer: 50mM 
sodium phosphate, 300mM NaCl, 10mM imidazole (pH 8.0). Elution buffer: 50mM sodium 
phosphate, 300mM NaCl, 250mM imidazole (pH 8.0). The other steps are same as GST 
purification. 
 
2.2.7. In Vitro Kinase assay: 
 
      To analyze TAK1 kinase activity, GST purified TAK1 (or TAK1-TAB1c68 fusion 
protein) was incubated with the recombinant 1 µM MKK6( K82A  or S207AT211A) , [γ-32 
P]ATP in the kinase buffer (50 mM Tris-HCl, pH 7.5, 0.5 mM DTT, 5 mM MgCl2, 50 µM 







2.3.1. The first 22 amino acids at the N-terminus did not stabilized TAK1. 
 
      It has been reported that that N-terminus 1 may play a negative role in regulation TAK1 
activity. To test if the N-terminus increased TAK1 stability, we make an N-terminus 
truncated form in which the first 22 amino acids were deleted.  The full-length and the 
truncated TAK1 were transfected into 293T cells. After 48 hours, cycloheximide 
(CHX) chase assay was performed to determine the protein stability. As shown in Fig. 27, the 
deletion of N-terminus did not increase the stability of TAK1. There was not much deference 
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Figure 27.  CHX chase assay for the full length TAK1 and TAK1ΔN22.  293T cells were 
transfected with the full length TAK1 and TAK1 TAK1ΔN22 plasmid. After 48 hours, cells 
were treated with 100 μg/mL CHX (Sigma) to inhibit protein synthesis and were harvested at 




2.3.2. TAK1 is stabilized by TAB1. 
 
      TAB1 was shown to augment the level of TAK1 [124].  To demonstrate the role of TAB1 
in regulating TAK1 activity, we firstly verified the existence of the interaction of TAK and 
TAB1 in 293T system. The different Flag-TAK isoforms were cotransfected with HA-TAB1 
into 293T cells. At 48 hours after transfection, cells were harvested and the extracts were 
immunoprecipitated by Flag antibody.  The immunoprecipitates were analyzed by western 
blot with HA antibody.   As shown in Fig. 28, all of four splicing forms, TAK1k63A and 
TAK1 ΔN22 were shown to interact with TAB1. We measured TAK1 level with or without 
TAB1 in 293T cell system. CHX chase assay was performed to measure TAK1 protein 
kinetics of the stability.  As indicated in Fig. 29, cotransfection of TAB1 significantly 
increased TAK1 protein level where did not change TAK1 mRNA level. TAK1 degraded 
very quickly after CHX treatment. CHX chase assay at several time points demonstrated that 
the half-life time TAK1 alone is less than 8 hours but TAK1 level did not change even 16 








Figure 28. TAB1 interacts with TAK1. The differnent Flag-TAK1 forms were tarnsfected 
with HA-TAB1 into 293T cells. The extracts were immunoprecipitated with Flag antibody 
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Figure 29.  TAK1 is stabilized by TAB1. Real time PCR was used to quantify TAK1 









2.3.3. TAK1 Ubiquitination level is not affected by TAB1. 
 
      Since TAK1 stability is regulated by TAB1, we proposed that TAK1 ubiquitination is 
regulated by TAB1. To test this hypothesis, the standard ubiquitination assay was performed 
in 293Tcells. Flag-TAK1 plus HA-ubiquitin plasmids with or without TAB1 were transfected 
into 293T cells. At 48 hours post-transfection 293T cells were treated with proteasome 
inhibitor MG132 at the final concentration of 50 μM for 6 h and then harvested 
for immunoprecipitation followed by western blot. As shown Fig.30, Coomassie blue 
staining or western blot demonstrated that TAK1 level was not affected by TAB1.  TNF-α 






































Figure 30.  Ubiquitination assay for TAK1.  Flag-TAK1 plus HA-ubiquitin with or without 
were transfected in to 293T cells. At 48 hours after transfection, cells were treated with 
proteasome inhibitor MG132 for 6 hours.  Then cells with or without TNF-α treatment for 30 
minutes were harvested for immunoprecipitation using flag antibody. The precipitates were 









2.3.4. TAB1 is indispensable for TAK1 kinase activity. 
 
      To test TAK1 kinase activity, we performed a series of experiments to analyze TAK1 
downstream targets and substrates.  Overexpression in 293T cells demonstrated that TAB1 is 
phosphorylated by TAK1. As in Fig. 31 A, the kinase activity of all the different TAK1 
forms including the splicing isoform a, b, c and d depends on TAB1.  TAB1 is also required 
for the kinase activity of the terminal truncated form TAK1 ΔN22. TAB1 was 
phosphorylated by the different TAK1 splicing isoforms a, b, c, d and TAK1 ΔN22 but not 
the kinase dead form TAK1K63A.  The phosphorylated TAB1 is reduced by phosphatase 
treatment (Fig. 31B). TAB1 is phosphorylated by TAK1a and TAK1a in a dose dependent 
manner since TAB1 phosphorylation is increased with the amount of transfected plasmid 
TAK1a and TAK1c as indicated in Fig. 31C.  TAK1 k63A serves as a dominant mutant as it 













Figure 31.  TAB1 is stabilized and phosphorylated by TAK1.   A. TAB1 is 
phosphorylated by TAK1 splicing variants.  B.  TAB1 is dephosphorylated by phosphatase. 
C. TAB1 is phosphorylated by TAK1 in a dose-dependent. D. TAK1 K63A acts as a 
dominant negative control. 
 







  TAK1 stabilization and phosphorylation also requires TAB1. To demonstrate that effects of 
TAB1 on the stabilization of TAK1, we used phosphatase to treat extracts and made a bunch 
of different dilutions for the extracts from TAK1-TAB1 cotransfection. As shown in Fig. 32, 
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Figure 32.  TAK1 stabilization and autophosphorylation depend on TAB1. TAK1 and 
TAB1 were transfected into 293T cells and TAK1 level was analyzed by western blot. 









As introduced before, TAK1 is required for NF-κB activation. We measure NF-κB activity 
induced by TAK1.  TAK1 with or without TAB1 were transfected into 293T cells. Nucleus 
extracts were fractionated and used for EMSA. As shown in Fig. 33, NF-κB activation was 
induced by TAK1 combined with TAB1 but TAK1 alone does not have much effect on NF-
κB activation. The splicing variants TAK1 c or TAK1 d were not shown to inhibit on NF-κB 
activation induced by TAK1a with TAB1. Although TAK1a or TAK1c alone did have effects 
on JNK phosphorylation, TAK1a plus TAB1 induced the phosphorylation of JNK (Fig.34). 
The isoform TAK1c with TAB1 induced the phosphorylation of JNK in a dose dependent 






















































Figure 33.  NF-κB activation is induced by TAK1 and TAB1. TAK1a with or without 
TAB1 plus the different amount of TAK1c or TAk1d plasmids were transfected into 293T 













Figure 34.  The phosphorylation of JNK is induced by TAK1 together with TAB1. 
TAK1 with or without TAB1 plasmids were transfected into 293T cells. JNK 









2.3.5. C-terminus of TAB1 is required and sufficient to activate TAK1. 
      To map the functional domain of TAB1 which stabilizes TAK1, we made a series of 
deleted TAB1 forms. These TAB1 deletion forms with Flag-TAK1 were transfected into 
293T cells. At 48 hours after transfection, cells were harvested for western blot. As shown in 
Fig. 35, our data confirmed that the N-terminal 418 could not stabilize and activate TAK 
[237]. The C-terminal region containing 68 amino acids is sufficient to stabilize and activate 
TAK.  We mapped the shortest peptide from TAB1 which is sufficient and required for 
TAK1 activation. This peptide contains only 17 amino acids (EPYVDFAEFYRLWSVD) 
between the C terminal site 10 and site 26.  The deletion of Glutamic acid (E) at the C26 or 
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     Figure 35.  TAK1 is stabilized by the C-terminus of TAB1.  Flag-TAK1 with the 
different HA-TAB forms was transfected into 293T cells.  TAK1 levels were analyzed by 
western blot with Flag antibody. 
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2.3.6. All four transcriptional isoforms of human TAK1 have kinase activity dependent 
on TAB1 but may be involved in different pathways. 
 
      As introduced before, four transcriptional variants have been identified in human [97, 98].  
To distinguish their functions, the four splicing isoforms of TAK1 were put back into TAK1 
null MEF cells using retrovirus infection.  The stable cell lines which express each splicing 
form were established by hygromicin selection. The stable cell lines were treated with TNF-α 
30 minutes. The nuleus proteins were isolated for EMSA. As shown in Fig. 36,  NFκB 
activation was induced by TNF-α  treatment in the cell lines expressing TAK1a and TAK1b. 
These results demonstrated that TAK1a nad TAK1b successfully rescued the phnotypes. 




Figure 36.  EMSA Assay for NF-κB activation in TAK1 rescue cells. Four splicing 
variants of TAK1 were put back into TAK1 null MEF cells. NF-κB activity induced by TNF-
α was analyzed by EMSA. 
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2.3.7. TAK1 activity is regulated by the acetylation at lysine 158. 
       
      Several reports have shown that TAK1 is regulated by post-translational modification 
such as phosphorylation and Ubiquitination [155, 238]. However, how TAK1 is stabilized 
and activated by TAB1 is still unknown. To answer this question, we made the TAK1-
TABC68 fusion and TAK1N303-TAB1C68 fusion constructs which expressed high active 
kinase (Fig.37A).  We tried to map the new PTM site on TAK1 using these two fusions 
constructs.  TAK1 with or without TAB, TAK1-TABC68 fusion and TAK1N303-TAB1C68 
fusion constructs were transfected into 293T cells. At 48 hours after transfection, the cells 
were collected and the extracts were immunoprecipitated by Flag antibody. The precipitates 
were resolved in SDS-PAGE gel and followed by Coomassie blue staining. As shown in 
Fig.37 B, TAK1 was successfully overexpressed in 293T cells and the interesting bands were 
excised from the gel and used for MASS SPEC analysis to identify the new post-translational 
modification. MASS spectra were summarized in the appendix. The identified amino acid 
sites were labeled in TAK1 sequence (Fig.38). Seven phosphorylation sites including Ser367, 
Ser375, Ser192, Ser389, Ser412, Thr440, and Ser441 were identified. Among the 
phosphorylation sites, Ser 192 and Ser412 were previously known and the other 
five are newly discovered phosphorylation sites. More important, five acetylation sites at 72, 














Figure 37. TAK1 is activated by TAB1.  A. Flag-TAK1, Flag-TAK1TAB1C68, Flag-
TAK1N303TAB1C68 with or without TAB1 were transfected into 293T cells. 
Phosphorylation of p38 and MKK3/6 were analyzed by western blot.  B. Flag-TAK1 with or 
without TAB1, Flag-TAK1TAB1C68, Flag-TAK1N303TAB1C68 were transfected into 
293T cells. The cells were harvested for immunoprecipitation using flag antibody. The 
precipitates were analyzed by Coomassie blue staining and the interesting bands were 
excised from the gel for MASS SPEC analysis. 
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  1 MSTASAASSS SSSSAGEMIE APSQVLNFEE IDYKEIEVEE VVGRGAFGVV  
 51 CKAKWRAKDV AIKQIESESE RKAFIVELRQ LSRVNHPNIV KLYGACLNPV  
101 CLVMEYAEGG SLYNVLHGAE PLPYYTAAHA MSWCLQCSQG VAYLHSMQPK  
151 ALIHRDLKPP NLLLVAGGTV LKICDFGTAC DIQTHMTNNK GSAAWMAPEV  
201 FEGSNYSEKC DVFSWGIILW EVITRRKPFD EIGGPAFRIM WAVHNGTRPP  
251 LIKNLPKPIE SLMTRCWSKD PSQRPSMEEI VKIMTHLMRY FPGADEPLQY  
301 PCQYSDEGQS NSATSTGSFM DIASTNTSNK SDTNMEQVPA TNDTIKRLES  
351 KLLKNQAKQQ SESGRLSLGA SRGSSVESLP PTSEGKRMSA DMSEIEARIA  
401 ATTGNGQPRR RSIQDLTVTG TEPGQVSSRS SSPSVRMITT SGPTSEKPTR  
451 SHPWTPDDST DTNGSDNSIP MAYLTLDHQL QPLAPCPNSK ESMAVFEQHC  
501 KMAQEYMKVQ TEIALLLQRK QELVAELDQD EKDQQNTSRL VQEHKKLLDE  
551 NKSLSTYYQQ CKKQLEVIRS QQQKRQGTS 
 
Phos:   Ser367, Ser375, Ser192, Ser389, Ser412, thr440, ser441  
Acetyl: Lys72, Lys158, Lys227, Lys520, Lys563  
 
 Figure 38.  PTM sites on TAK1 identified by MASS SPEC.  Seven phosphorylation sites 
and five acetylation sites were identified. 
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      To study the roles of phosphorylation at these sites in regulating TAK1 activity, Ser 389, 
Thr440 and Ser 441 were changed into alanine to abolish phosphorylation with the site 
mutagenesis.  The constructs containing the mutation at these sites were transfected with HA-
TAB1 into 293T cells. Three assays were used to evaluate TAK1 activity: TAK1 stability, 
TAB1 phosphorylation and κB promoter activity. As indicated in Fig. 39, the TAK1 mutants 













        Figure 39.  The effects of phosphorylation at the new identified sites on TAK1. Ser 
389, Thr440 and Ser441 were changed into alanine.  Western blot was used to analyze TAK1 




      It is a well established approach that arginine (R) is used as the mimics of unacetylated 
lysine and glutamine (Q) or asparagine (N) are used as the mimics of acetylated lysine due to 
the structural senilities (Fig. 41).  Taking this advantage, we change the lysine at 
72,158,227,520 and 563 into arginine or glutamine using the site mutagenesis approach.  We 
also change lysine 158 into asparagines. These TAK1 mutants were transfected with HA-
TAB1 into 293T cells. TAK1 activity was evaluated by TAK1 stability, TAK1 
phosphorylation, TAB1 phosphorylation and MKK6 phosphorylation. As shown in Fig. 42A, 
the changes from lysine to arginine or glutamine at sites 72, 227,520 and 563 did not have 
many effects on TAK1 activity based on the above assays. TAK1 kinase dead form K63A 
was used as the negative control for TAK1 activity. The different combinations of these 
mutations such as K72RK227R, K563RK72R, K563RK227R, K563RK520R, K72QK227Q, 
K72RK227RK563R (3R), K72RK227RK520RK563R (4R) also kept the same activity as the 
wild type. However, the change from lysine to arginine at 158 (TAK1 K158R and TAK1 5R 
mutant) abolished TAK1 activity Fig. 42B.  More important, the change from lysine to 
asparagine at 158 partially rescued TAK1 activity as indicated by TAK1 stability, TAK1 















     















4R: K72R, K227R, K520R and K563R
5R: K72R, K227R, K520R and K563R plus K158R
β-actin










  Figure 42.   The effects of acetylation at the new identified sites on TAK1. A.  Screening 
for the functional lysine sites on TAK1. Lys72, lys158, lys227, lys520 and lys563 were 
changed into arginine, glutamine or asparagine.  Western blot was used to analyze TAK1 
stability, TAK1 phosphorylation and TAB1 phosphorylation. B. The effect of acetylation at 
lys158 was verified. Asparagine partially rescues lysine phenotype at 158. 
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      We also performed in vitro kinase assay to study how TAK1 activity is regulated by 
TAB1.  TAK1, TAB1 and MKK6 were cloned into PET 28 (His tag) or PGEX (GST tag) 
systems. WT, K63A, K158R, K158Q, K158N. 4R, 5R and the deferent TAK1-TAB1 C68 
fusion bacterial expression constructs were transformed into BL-21 cells and the bacterial 
cultures were induced by IPTG.  The recombinant His-tag proteins were purified by Ni-NTA 
affinity resin and GST-tag proteins were purified by GSH beads. We also use site 
mutagenesis to produce MKK6 K82A kinase dead form in which ATP bind pocket is 
disrupted. As the substrate, MKK6 K82A rules out the possibility of autophosphorylation in 
the following experiments. MKK6 S207AT211A was used as the negative control in which 
the phosphorylation sites were abolished. As shown in Fig. 43, we successfully produced the 
GST tagged recombinant various TAK1 forms, TAB1 and the substrate MKK6 various forms 
were purified from bacteria expression system. Coomassie blue staining was performed to 








4R: K72R, K227R, K520R and K563R





Figure 43.   Recombinant GST-TAK, GST-TAB1 and GST MKK6 purified from 
bacterial. A.  The different GST TAK1 forms and GST-TAK1-TAB1C68 fusion forms. B. 






      The recombinant proteins were used for in vitro kinase assay. As indicated in Fig. 44 and 
Fig. 44, our data clearly demonstrated that only the recombinant TAK1-TAB1 C68 fusion 
protein could phosphorylate itself and MKK6 K82A while TAK1 alone does not have any 
kinase activity MKK6 are phosphorylated specifically at Ser 201 and T 211A since  
S207AT211A form could not be phosphorylated by the fusion protein and thereby (Fig. 45).  
Surprisingly, we did not detect the TAK1 kinase activity in the reaction using the 
combination of TAK1 and TAB1 which were separated purified from bacteria (Fig. 44). 
Using His-tag or GST-tag TAK1, we demonstrated that TAK1 could be immunoprecipitated 
by TAB1 antibody (Fig. 46A) and conversely TAB1 could be immunoprecipitated by TAK1 









      Figure 44.  TAK1 in vitro kinase assay.  TAK1 mutants at lysine 158 were produced by 
site mutagenesis. TAK1 variants, TAB1 and MKK6K82A were purified from bacteria and 
used for in vitro kinase assay labeled with [γ-32 P] ATP. TAK1-TAB1 C68 fusion protein was 












Figure 45.  TAK1 in vitro kinase assay. TAK1 mutants at lysine 158 were produced by site 
mutagenesis.  TAK1 variants, TAB1, MKK6K82A and MKK6 S207AT211A were purified 


















Figure 46.  TAK1 and TAB1 interact with each other in vitro. A. Binding reaction was 
performed by GST-TAK1 and GST-TAB1. Immunoprecipitation was performed with TAK1 
or TAB1 antibody and immunoblotting was performed with TAK1 antibody. B. Binding 
reaction was performed by GST-TAK1 and GST-TAB1. Immunoprecipitation was 
performed with TAK1 or TAB1 antibody and immunoblotting was performed with TAB1 
antibody. B. Binding reaction was performed by His-TAK1 and GST-TAB1. 






      We also generated TAK1 kinase from 293T cells. The different Flag-TAK1 forms with 
HA-TAB1 were transfected into 293T cells. At 48 hours post transfection, the cells were 
harvested and the TAK-TAB1 complexes were immunoprecipitated by flag antibody. The 
precipitates were used for in vitro kinase assay.  The recombinant GST-MKK6 kinase dead 
form was used for the kinase reaction. As shown in Fig. 47, TAK1 kinase activity was 
significantly reduced by the change from lysine to arginine at 158. More importantly, TAK1 
K158N mutant partially recue the TAK1 kinase activity which consentient with the above 









   Figure 47.  TAK1 in vitro kinase assay. The different Flag-TAK1 forms with HA-TAB1 
were transfected into 293T cells. At 48 hours post transfection, the cells were harvested and 
the TAK-TAB1 complexes were immunoprecipitated by flag antibody. The precipitates were 






      To demonstrate the important role of TAK1 acetylation at lysine 158, we performed a 
series experiments in MEF cells. Firstly, the TAK1 forms including TAK1 wild type, TAK1 
K158R, TAK1 K158Q, TAK1 K158N and the empty vector were put back into TAK1 null 
MEF cells and the stable cell lines expressing the various forms were established by the 
selection of zeocine. TAK1 expression was verified by western blot.  The cells were treated 
by TNF-α for different times and several experiments were performed to investigate the role 
of lysine 158 in regulating TAK1 activity. 
 
      Firstly we tracked the morphological changes of the cells expressing the different TAK1 
forms after TNF-α treatment under microscope.  As indicated in Fig. 48, a lot of TAK1 null 
cells and the empty vectors cells were dead at 4 hours after TNF-α treatment. No phenotypic 
changes were observed in WT rescue cells.  TAK1 K158R cells displayed a partially rescue 
phenotype but K158Q and K158N cell had a better rescue phenotype than TAK1 K158R.  At 
24 hours after   TNF-α treatment, almost all of TAK1 null cells and the empty vectors cells 
clogged, floated and underwent apoptosis. Most of K158R cells were also dead but survival 
cells were a little more than TAK1 null cells and the empty vectors cells.  This was still some 
K158 N cells alive. It is not surprised that WT TAK1 had the most survival cells.   As 
summary, the rescue effects followed the order: WT > K158N > K158Q > K158 N > K158 R> 












Figure 48. Light-microscopic phenotype in MEF cells expressing the various TAK1 
forms or the empty vector as control.  The cells were treated with TNF-α and the 





      We also performed EMSA to evaluate NF-κB activation.  As shown in Fig 49, only WT 
rescue cells displayed the early NF-κB induction by TNF-α treatment at 30 minutes. TAK1 
K158R, TAK1 K158Q and TAK1K158 N exhibited a later NF-κB induction at 8 hours and 
displayed different pattern from TAK1 null cell or the empty vectors which showed a slower 
decreasing process. 








Figure 49. NF-κB activation induced by TNF-α treatment. Nuclear extracts were isolated 
from the different cell lines at several time points as indicated and used for EMSA to 
measure NF-κB activation. 
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      The expression of TAK1 rescues the TNF-α induced apoptosis in TAK1Δ/Δ MEFs, and 
TAK1 K158Q and TAK1 K158N showed partially rescue effect. At 4 hours after TNF-α 
treatment,  although K158 Q, K158N and K158 R showed less PARP cleavage than the 
TAK1 null cells and the empty vector cells, TAK1 K158Q and TAK1 K158N cells had a 
better rescue effect than K158R.  TAK1 K158Q and TAK1 K158N cells also had a stronger 
the induction of MKK6 phosphorylation than K158R.  The phosphorylation of MKK6 level 
was close to the TAK1 null cells and the empty vector cells.  Interestingly, the basal level of 
phosphor-ERK without TNF-α treatment displayed a decreasing order: WT < K158N < 
K158Q < K158 N < K158 R< the empty vector, TAK1 null cells. It seemed that phosphor-
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Figure 50. The Expression of TAK1 Rescues the TNF-α Induced Apoptosis in TAK1Δ/Δ 
MEFs, and TAK1-K158Q and TAK1-K158N Showed Partially Rescue Effect. The cells 
were harvested at 4 hours after TNF-α treatment followed by western blot using the different 






      We also evaluated apoptosis cells using Annexin-V staining.  As shown in Fig. 51, TAK1 
wild type rescue cells, K158 N cells and K 158 Q cells displayed much slower apoptosis 
kinetics than TAK1 K158R cells, the empty vector cells and TAK1 null cells.  At 24 hours 
after TNF-α treatment, more than 50% of TAK1 K158R cells, the amply vector cells and 
TAK1 null cells showed Annexin-V positive, however, less than 30% of TAK1 wild type 
rescue cells, K158 N cells and K 158 Q cells were Annexin-V positive.  Once again, the 
rescue effects followed the order: WT > K158N > K158Q > K158 N > K158 R> the empty 
vector, TAK1 null cells.  
 
Figure 51.  Annexin V staining for apoptosis assay. The cells were collected at the 
different time points after TNF-α treatment and followed by Annexin V Staining. Annexin V 
positive cells were indicated with percentage. 
170 
 
      Flow Cytometry Analysis was also performed to evaluate apoptosis.  As indicated in Fig. 
52, at 24 hours after TNF-α treatment, most of TAK1 null cells and the empty vector cells 
underwent apoptosis.  TAK1 K158R cells showed a partially rescue effect while WT TAK1 
rescue cells, TAK1 K158N cells and TAK1 K158Q cells displayed better rescue effects. 
Consistent with the results from PARP cleavage, annexin-V staining, the rescue effects 
followed the exact same order: WT > K158N > K158Q > K158 N > K158 R> the empty 



















Figure  52.   Flow Cytometry analysis for apoptosis assay. The different cell lines were 




2.3.8. TAK1 is acetylated by CREB-binding Protein (CBP) 
 
      To screen for the acetyltransferase, we transfected Flag-TAK1 with or without TAB1 and 
the several acetyltransferase constructs into 293T cells.  TAB1 was used to increased TAK1 
level. The cells were harvested at 48 hours after transfection and the extracts were 
immunoprecipitated by Flag antibody followed by western blot with acetyl lysine antibody. 
Our results demonstrated that the acetylation of TAK1 was significantly increased by CBP 
but not p300, GCN5 and PCAF (Fig. 53).  We also examined the acetylation level of TAK1 
4R and TAK1 5R mutants. As shown in Fig. 56, the acetylation level of these two mutants 
was deduced compared with wild type TAK1 and TAK1 K158R.  It seemed that TNF-α 














      Figure  53. TAK1 acetylation is induced by CBP. Flag-TAK1 and the acetyltransferase 
constructs CBP, p300, GCN5 and PCAF were transfected into 293T cells. The cells were 
harvested at 48 hours after transfection and the extracts were immunoprecipitated by Flag 








4R: K72R, K227R, K520R and K563R




Figure  54. Acetylation level of TAK1 4R and TAK1 5R mutants is less than TAK1 wild 
type. Flag-TAK1 and the acetyltransferase constructs CBP were transfected into 293T cells. 
The cells were harvested at 48 hours after transfection and the extracts were 
immunoprecipitated by Flag antibody.  Acetylated-TAK1 was demonstrated by western blot 






      We also tested the effects of two deacetylase inhibitors trichostain A and nicotianamine. 
As shown in Fig. 55, nicotianamine but not trichostain A treatment significantly increased 
the acetylation level of TAK1 compared with untreated control. The combined treatment had 

























Figure 55. Acetylation level of TAK1 is increased by the treatment of deacetylase 
inhibitor nicotianamine. The 293 cells were transfected with Flag-TAK1 and treated with 
deacetylase inhibitors trichostain A and nicotianamine. Acetylated TAK1 was analyzed by 








2.3.9. Lysine 158 of TAK1 is conserved throughout all kinases 
 
      We firstly aligned the kinase domain of different kinases using the software MEGA4 
followed by a manual adjustment. As shown in Fig. 56, lysine 158 of TAK1 is conserved 














C.elegans_MOM-4  WMFQLSSAVDFFHSNS---QVHRDLKLQNMLLSDRYRT 
Drosophila_tak1  WARQCAEGLAYLHAMTPKPLIHRDVKPLNLLLTNKGRN 
zebrafish_tak1   WCLQCSQGVSYLHGMKPKALIHRDLKPPNLLLVAGGTV 
Xenopus_tak1     WCLQCAQGVAYLHSMKPKALIHRDLKPPNLLLVAGGTV 
mouse_tak1       WCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGGTV 
rat_tak1         WCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGGTV 
human_tak1       WCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGGTV 
 
A-raf      MVQLIDVARQTAQGMDYLH---AKNIIHRDLKSNNIFLHEG-- 
B-raf      MIKLIDIARQTAQGMDYLH---AKSIIHRDLKSNNIFLHED-- 
map3k1     ESVVINYTEQLLRGLSYLH---ENQIIHRDVKGANLLIDST--- 
map3k2     ENVTRKYTRQILEGVHYLH---SNMIVHRDIKGANILRDS---- 
map3k3     ESVTRKYTRQILEGMSYLH---SNMIVHRDIKGANILRDS---- 
map3k4     EHVIRLYSKQITIAINVLH---EHGIVHRDIKGANIFLTS---- 
map3k5     EQTIGFYTKQILEGLKYLH---DNQIVHRDIKGDNVLINTY--- 
map3k6     ESTISFYTRQILQGLGYLH---DNHIVHRDIKGDNVLINTF--- 
map3k7     AAHAMSWCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGG-- 
map3k8     EFEIIWVTKHVLKGLDFLH---SKKVIHHDIKPSNIVFMS---- 
map3k9     PDILVNWAVQIARGMNYLHDEAIVPIIHRDLKSSNILILQKVEN 
map3k10    PHVLVNWAVQVARGMNYLHNDAPVPIIHRDLKSINILILEAIEN 
map3k11    PHVLVNWAVQIARGMHYLHCEALVPVIHRDLKSNNILLLQPIES 
map3k12    PSLLVDWSMGIAGGMNYLH---LHKIIHRDLKSPNMLITYD--- 
map3k13    PRLLVDWSTGIASGMNYLH---LHKIIHRDLKSPNVLVTHT--- 
map3k14    EDRALYYLGQALEGLEYLH---SRRILHGDVKADNVLLSSD--- 
map3k15    EPTIKFYTKQILEGLKYLH---ENQIVHRDIKGDNVLVNTY--- 
raf1       MFQLIDIARQTAQGMDYLH---AKNIIHRDMKSNNIFLHEG--- 
ZAK        MDHIMTWATDVAKGMHYLHMEAPVKVIHRDLKSRNVVIA----- 
     Figure 56.    K 158 of TAK1 is highly conserved in most of kinases.  Alignment was 
performed with the software MEGA4 followed by a manual adjustment. The conserved 
lysine was highlighted by red color. 
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      Therefore, we tested the role of this lysine in controlling kinase activity of MEKK3.  We 
made three MEKK3 mutants K522R, K522Q and K522N.  Kinase activity was examined by 
phosphorylation antibody.  As shown in Fig. 57, the substation of lysine with arginine, 
glutamine or asparagine at position 522 which is corresponding to lysine 158 of TAK1 

















Figure 57. Lysine 522 is required for MEKK3 kinase activity. Site mutagenesis was used 
to create MEKK3 K522R, K522Q and K522N mutants.  The various MEKK3 constructs 










      MEKK3 was also acetylated by CBP. HA-MEKK3 and the acetyltransferase constructs 
CBP, p300, GCN5, PCAF and tip60 were cotransfected into 293T cells. The cells were 
harvested at 48 hours after transfection and the extracts were immunoprecipitated by HA 
antibody.  Acetylated-MEKK3 was analyzed by western blot with acetyl lysine antibody. As 

















Figure 58. MEKK31 acetylation is induced by CBP. HA-MEKK3 and the 
acetyltransferase constructs CBP, p300, GCN5, PCAF and tip60 were transfected into 293T 
cells. The cells were harvested at 48 hours after transfection and the extracts were 
immunoprecipitated by HA antibody.  Acetylated-MEKK3 was demonstrated by western blot 











      In the current study, we investigate the three regulatory mechanism3: 1. N-terminus of 
TAK1; 2. TAK1 binding protein TAB1; and 3. Post-translational modification, especially 
acetylation at lysine 158. 
 
      Several independent studies have demonstrated that TAK1 with N-terminus truncated has 
more activity than full-length TAK1. Ectopic expression of mouse TAK1ΔN has more severe 
effect than that of full length mTAK1 in transgenic flies [81]. The injection of TAK1∆N 
mRNA encoding the N-terminal truncated TAK1 induced apoptosis at lower doses than the 
full length TAK1 [85]. TAK1ΔN stimulated TGF-β target gene PAI-1 expression [75]. These 
results strongly implicated that TAK1 function is regulated by the N-terminus.   We 
compared the stability of TAK between full length and N-terminus truncated form using the 
classic cycloheximide (CHX) chase analysis. Both full length TAK1 and TAK1ΔN were 
degraded in a time-course experiment after CHX treatment.  We did not see much difference 
in dynamics between them. In our experiments, either full length TAK1 or TAK1ΔN alone 
does not have kinase activity. Both full length TAK1 and TAK1ΔN were stabilized by the 
co-expression of TAB1. It seems that at least human N-terminus of TAK1 is not related to 
stability. The mechanism of TAK1 N-terminus regulation may be species-dependent. 
Another explanation is that the N terminus may be involved in TAK1 function other than 
stability. More experiments are needed to define how it is involved with TAK1 activity. 
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      The previous study showed that TAB1 increased the expression level of TAK1 [124].  
Here, we provided new evidence to understand the underlying mechanism. Real time PCR 
result showed that TAB1 did not increase TAK1 transcription. Furthermore, using 
cycloheximide (CHX) chase analysis we demonstrated that most of TAK1 was degraded 
after 16 hours of CHX treatment.  However, co-expression of TAB1 significantly protected 
TAK1 from degrading in the presence of CHX. As far as we know, this is the first evidence 
that TAK1 is stabilized by TAB1 at the protein level. TAK1 alone is not stable. As discussed 
before, we also tested TAK1ΔN stability. Our experiments demonstrated that the deletion of 
TAK1 did not augment stability and TAK1ΔN stability also required TAB1.  So the 
mechanism in which TAB1 stabilizes TAK1 may be N-terminus independent. In the 
physiological condition, TAK1 constitutively interacts with TAB1.  This interaction is very 
important and may play a necessary role in controlling TAK1 activity. 
 
      To understand the mechanism how TAK1 is regulated by TAB1, we analyze TAK1 
Ubiquitination level and tried to locate TAK1 Ubiquitination sites using MASS-SPEC 
approach. However, we did not observe much difference in TAK1 Ubiquitination between 
with and without TAB1.   We also could not detect any Ubiquitination peptides of TAK1 
with MASS SPEC (data not known). Most of proteins are degraded by the attachment of 
ubiquitin. However, some proteins were degraded through an ubiquitin-independent 
mechanism [239-242].  Such mechanisms may be involved with TAK1 degradation.  
However, we cannot rule out the possibly that Ubiquitination of TAK1 is a transient event 
and the approaches we used was not sensitive enough to detect TAK1 Ubiquitination. 
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      A lot of studies have proposed that TAK1 kinase activity depends on TAK1 [85, 124, 
243-246]. Our data recapitulated the role of TAB in regulating TAK activity and gave more 
evidence that TAB1 plays an essential role in regulating TAK1 activity. 
 
      The several signaling pathways, including TAK1 autophosphorylation, TAB1 
phosphorylation, MKK6 phosphorylation, NF-κB promoter activity were induced by 
coexpression of TAK1 and TAB1.  In our experiments, transfection of TAK1 alone, without 
TAB1, did not have any function.  However, transfection of TAK1 alone, without TAB1, did 
not have any function in all of these experiments.  These results strongly support that TAK1 
activity requires TAB1.  
 
      In vitro kinase assay using bacterially expressed recombinant protein is a very simple but 
powerful technique.  This approach can rule out contamination by other kinases. To take the 
advantage of this approach, we first revealed that GST-TAK1-TAB1 fusion protein purified 
from bacterial has high kinase activity.  Since the substrate MKK6 itself is a kinase, we made 
a kinase dead mutant of MKK6 to overcome its autophosphorylation in kinase assay. As 
demonstrated in fig, GST-TAK1-TAB1 phosphorylated itself and MKK6 kinase mutant. 
Mutations Ser207 and Thr211 at these two site abolished MKK6 phosphorylation. These 
results confirmed that these two sites of MKK6 are specifically phosphorylated by TAK1. 
However, GST-TAK1 alone does not have any kinase activity.  This experiment clearly 
demonstrated the requirement of TAB1 for TAK1 activity.  
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      Since we demonstrated before that TAK1 could play an oncogenic in pancreatic cancer 
development, TAK1 is an attractive drug candidate.  TAK1 inhibitors may be used as a 
promising therapeutic approach.  Unfortunately, TAK1 alone does not have any kinase 
activity and therefore it cannot directly be used for screening inhibitors. Our fusion protein, 
which has high kinase activity, may provide a new assay for the screen of TAK1 inhibitors. 
 
      We also purified TAK1 and TAB1 separately. However, combination of TAK1 and 
TAB1 proteins did not produce kinase activity.  This inactivation of kinase was not due to the 
loss of the interaction between TAK1 and TAB1 because we verified the interaction still 
existed using co immunoprecipitation experiment.  In the kinase reaction, we demonstrated 
that TAK1 can be pulled down by TAB1.  Furthermore, we showed that this interaction was 
not resulted from GST since we observed the interaction between TAK1 and TAB1 using 
His-TAK1 purified from TAK1. These experiments demonstrated that the interaction of 
TAK1 and TAB1 was not sufficient to induce kinase activity. Some additional mechanism 
besides TAK1-TAB1 interaction may be required for TAK1 activity.   One possibility is that 
TAB1 may be involved in TAK1 folding. In bacterial expression system, TAK1 could not 
form an active conformation and subsequently lost kinase activity. More experiments need to 
be carried out to delineate its  
 
      It was reported that C-terminus of TAB1 is required for TAK1 activation [124].  Our data 
confirmed the previous discovery and mapped a minimum peptide sequence at the c-terminus 
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of TAB1 which is necessary for TAK1 activation. We made a series of deletion mutants of 
TAB1 and defined that the short peptide from the c-terminus of TAB1 
“EPYVDFAEFYRLWSVD” is not only required but also sufficient for TAK1 activation.  
The deletion of an amino acid glutamic acid (E) at the N-terminus of this peptide completely 
abolished TAK1 kinase activity.  Homolog blast reveled that this sequence was found only in 
TAB1 protein. This result demonstrated that the function of this sequence is very specific. 
 
      Unlike most other kinases, TAK1 alone does not have kinase activity. Only when 
interacted with TAB1, does it have kinase activity.    The requirement of TAB1 for TAK1 
kinase activity is quite unique. However, why TAK1 is activated by such a short peptide is a 
challenge question.  This peptide-kinase interaction may be very similar with the ligand-
receptor binding. It should be noticed that a majority of amino acids containing this peptide 
are hydrophobic.  The interaction of this peptide with TAK1 may help change its kinase 
conformation, for example, to increase ATP affinity. However, the evidence is still largely 
absent. The data from structure biology may be required to reveal the detailed mechanism. 
 
      As introduced before, four transcriptional variants have been identified in human.  All of 
these isoforms interact with TAB1.  Since alternative splicing in TAK1 C and D results in a 
reading frame shift and an earlier stop codon, the c-terminus of TAK1 is required for its 
TAB2 binding.  TAB1 was phosphorylated by TAK1 since overexpression of different 
TAK1 transcriptional variants with TAB1 resulted in TAB1 phosphorylation and TAK1 
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kinase dead form (K63A) was unable to induce phosphorylation.  Cooverexpression of 
TAK1 and TAB1 also resulted in JNK phosphorylation and NF-κB activation.  In fact, the 
kinase domain is complete in these four transcriptional variant and thereby it is not surprised 
that all of them have kinase activity.  
 
      However, this does not mean their functions are completely overlapping.  TAK1 A, 
TAK1 B and TAK1C, TAK1 D may have different functions. Using TAK1 null MEF cells as 
the parental cell line, we made the stable cell lines expressing human TAK1A, TAK B, TAK 
C and TAK D.  Interested, the rescue experiments in TAK1 null MEF cells demonstrated that 
only isoform TAK1 A and TAK1 B, but not TAK C and TAK1 D can restore NF-κB activity 
induced by IL-1 and TNF-α.  It has been shown that TAK1 c-terminus [(TAK1 403-579)] 
was required and sufficient for TAB1 binding [124]. TAB2 is an adapt protein which mediate 
the interaction of TAK1 and TRAF6 and regulates NF-κB activation induced by IL-1 [125]. 
The alternative splicing in TAK1 C and D results in a reading frame shift and an earlier stop 
codon and thereby lost the binding to TAB2.  Consequently, TAK C and TAK1 D can no 
longer bind TRAF6 and thereby NF-κB cannot be activated through TAK C and TAK1 D.  
Our data showed that TAK C and TAK1 D may not be involved in NF-κB activation and 
they may play different roles in specific tissue or at different developmental stage.  However, 
what’s the deference in roles between TAK1 A and TAK1 B, or between TAK1 C and TAK1 
D is still unknown.  These splicing variants may be development stage specific or tissue 
specific. The current research is limited in NF-κB signaling pathway.  However, they could 
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be involved in the different signaling pathways in response to the deferent stimuli.  More 
experiments will be necessary to distinguish their functions. 
 
      TAK1 function is also regulated by post-translational modification.  It has been showed 
that autophosphorylation of Thr 178, Thr 184 , Thr 187 and Ser 192  in activation loop is 
required for TAK1 activation [247-249]. Mutations at these sites abolished TAK1 kinase 
activity.  
 
      As discussed before, TAK1 was largely stabilized by TAB1.  Taking advantage of co-
overexpression of TAK1 and TAB1 in 293T cells, we tried to identify some post-
translational modification sites of TAK1. A total of 7 phosphorylation sites were identified in 
TAK1 (Ser192, Ser367, Ser375, Ser389, Ser412, Thr440 and Ser441).  Some of these 
phosphorylation sites (Ser192, Ser375 and Ser412) have been identified before [155] and the 
other sites were identified first in this study.  To study the roles of phosphorylation sites at 
these sites, we uses site mutagenesis to change serine or threonine into alanine. Although 
mutation of serine or threonine at Ser389, Thr440 and Ser441 to alanine abolished 
phosphorylation at these sites, TAK1 autophosphorylation level or TAB1 phosphorylation 
was not affected. Therefore, phosphorylation of TAK1 at these sites is not required for 
activation. However, we cannot exclude the possibility that these phosphorylation events 





      More important, several acetylation sites were identified in our study. As introduced 
before, acetylation is a very important post-translational modification.  Here we firstly 
demonstrated that TAK1 is regulated by acetylation.  A total of 5 acetylation sites were 
identified in TAK1 (Lys72, Lys158, Lys227, Lys520 and Lys563).  As far as we know, this 
is the first time that lysine acetylation was identified in TAK1.  As shown Fig. 61, both lysine 
and arginine are positively charged and they have the similar side chain. However, arginine 
cannot be acetylated at ε-amino group, so it is used as the mimics of unacetylated lysine in 
study of protein biochemistry. The positive charge is removed in lysine by acetylation at ε-
amino group. In addition, it is a well established approach that glutamine or asparagine is 
used as the mimics of acetylated lysine.  
  
      To understand the roles of acetylation sites at these sites, we uses site mutagenesis to 
change lysine into arginine or glutamine or asparagine.   We used the following different 
assays to determine TAK1 activity.  
      (1) As discussed before, when co expressed with TAB1 in 293T cells, TAK1 is 
phosphorylated by itself. However, TAK1 kinase dead form K63A, in which ATP binding 
pocket was mutated, does not have kinase activity; 
      (2) TAK1is stabilized by TAB1 when co-expressed in 293T cells but the level of TAK1 
K63A are not affect by TAB1; 
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      (3) TAK1, but not TAK1 K63A, can stabilize TAB1;  
      Our results showed TAK1 activity was not affected by mutations at Lys72, Lys227, 
Lys520 and Lys563. To determine if these sites have redundant function, we made the 
different combined mutant at these four sites.  As shown in fig, the double mutants 
K72RK227R, K72RK563R, K227RK563R, K520RK563R, and K72QK227Q displayed the 
same activity as the wild type TAK1. Furthermore, the triple mutant K72RK227RK563R 
(called TAK1 3KR) also had the same kinase activity as the wild type TAK1. Finally, even 
the quad mutant in which all of the four lysine sites were mutated to arginine (TAK1 4KR) 
still held its kinase activity. These data clearly demonstrated these four sites are not involved 
with TAK1 kinase activity. However, we cannot rule out the possibility that acetylation at 
Lys72, Lys227, Lys520 and Lys563 is involved in other mechanism independent of TAK1 
kinase activity. 
 
      Surprising, the change of lysine 158 resulted in the loss of TAK1 kinase activity 
according to above 4 assays.  It is unexpected that glutamine or asparagine substitution 
mimicked acetylation at lysine 158 in our experiments. As mentioned before, we established 
a kinase active form in bacterial expression system, which is a fusion protein, composed of 
TAK1 and C-terminus of TAB1.  We changed the lysine 158 of the fusion protein into 
arginine or glutamine or asparagines. In vitro kinase assay clearly showed that TAK1 kinase 




      More important, the lysine acetylation mimics glutamine or asparagine at 158 of TAK 
partially rescue TAK1 function in survival and anti-apoptosis pathway. NF-κB activation 
induced the expression of antiapoptotic gene such as Bcl-2 and Bcl-x [250].  It is well known 
that the cells lacking NF-κB would experience apoptosis upon TNF-α stimulation [251]. To 
study role of lysine 158 in controlling TAK1 function, we resorted the expression of TAK1 
including K158R, K158Q and K158N mutants in TAK1 deficient MEF cells.  Morphological 
and   flow cytometry analysis demonstrated that TAK1 deficient cells and the cells 
containing the empty vector only cells experienced massive death at four hours after TNF-α 
treatment.  It is not surprised that the cells were totally rescued from apoptosis by the 
expression of wild type TAK1 at different time points.  More interesting, the cells were 
partially rescued by TAK1 K158R, K158Q and K158N.  Most importantly, K158Q and 
K158N mutants had even better effects of rescue than K158R.  These results are consistent 
with Poly (ADP-ribose) Polymerase (PARP) cleavage analysis and annexin-V staining.  
 
      It should be noticed that although TAK1 K158R did not display any kinase activity in our 
kinase assay, it still displayed a partially rescue effect. One explanation is that TAK1 k158R 
still has residual kinase activity. This kind of residual kinase activity could not be sensitive 
enough for our detection approach but it could still partially rescue the phenotype. Another 
explanation is that TAK1 served as not only a kinase, but also a scaffold for the other IKK 
kinase such as MEKK3 and thereby complement for the loss of TAK1 kinase activity.  In 
fact, IKK complex is composes of a lot of proteins.  It is possible that TAK1 provide a 
scaffold for the other components. We need more evidence to test this possibility. 
192 
 
      It should also be noticed that although TAK1 K158N purified from 293T cells displayed 
a partially kinase activity, we did not detect kinase activity using GST-TAK1K158N 
TAB1C68 fusion. One possibility is that the recombinant TAK1 kinase purified from 
bacterial lacks some modifications which are important for kinase activity. GST- WT 
TAK1K TAB1C68 fusion alone has high activity and therefore does not requires these 
modifications.  
 
      Lysine can be methylated, ubiquitinated and acetylated. These modifications can be 
regulated by each other since they compete for the same site. The study of acetylation is 
focused on histone although the increasing evidence demonstrated that acetylation also plays 
an important role in regulating non-histone proteins. Our study provides a new mechanism in 
which kinase activity is regulated by acetylation. 
 
      We also identified CBP as the acetyltransferase of TAK1. The histone 
acetyltransferase (HAT) CBP was originally identified as a transcriptional coactivator 
involved in histone modification.  It interacts with cAMP-response element-binding protein 
(CREB) and subsequently regulates the transcription of target genes [252-256].  A lot of 
studies have showed that CBP also acetylated the non-histone proteins such as p53 CBP 
[257-261].  To identify the acetyltransferase of TAK1, we expressed TAK1 with several 
candidates including CBP, P300, GCN5, PCAF and Tip60.  Acetylation of TAK1 was 
significantly increased by the expression of CBP. Therefore, CBP is a potential candidate 
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which acetylates TAK1. We are still unable to rule out the possibility that TAK1 is the 
substrate of other acetyltransferases since our list is not complete.  We also tested other 
kinase such as MEKK3, TAK1-TAB1 C68 fusion, PLK3 and found that these kinases also 
were acetylated by CBP. It may be a common mechanism that kinase activity is regulated by 
acetylation.  
 
      We firstly aligned the kinase domain of different kinases using the software MEGA4 
followed by a manual adjustment. As shown in fig, lysine 158 of TAK1 is conserved from c. 
elegans to human. It is also invariable in all of MAP3K members. Moreover, it is conserved 
in all of kinase. Therefore, we tested the role of this lysine in controlling kinase activity of 
MEKK3. As shown in fig, the substation of lysine with arginine, glutamine or asparagines at 
position 522 which is corresponding to lysine 158 of TAK1 abolished its kinase activity.   
These data demonstrated that the conserved lysine is very important for kinase activity. This 
conserved domain has been identified before but its role in controlling kinase activity is 
unknown. Our discovery provide a new mechanism and highlight that acetylation at this 
conserved site may be a common regulatory mechanism of kinase activity. However, we did 
not observe kinase activity in the mutants MEKK3 K522Q or MEKK3 K522N. One 
explanation is that the kinase activity is very week so that the MEKK3 phosphorylation 
antibody is not sensitive enough for detecting the activity.  We could rule out possible that 
although this site is conserved, the acetylation mechanism is still depended on the specific 




      There are still unanswered questions.  Since acetylation is reversible process, the 
deacetylase which counteracts CBP is still unknown. The future plan includes screening for 
the deacetylase and understanding the underlying mechanism how acetylation at this site 
regulates kinase activity is still unknown. The acetylation is normally low in vivo.  The pan 
acetyl lysine antibody cannot give us any information about the specific information. To get 
accurate and detailed knowledge about acetylation efficiently, the site specific antibody is 
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